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Osteoporosis and resultant fractures 
are an increasing health problem 
worldwide. The early detection of 
possible risk factors can help the pre-
vention of osteoporosis. This study 
investigated whether life satisfaction, 
depression and use of antidepres-
sants are associated with bone health 
using two large population based 
cohorts. 
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ABSTRACT 
 
Osteoporosis and resultant fractures are an increasing health problem especially among the 
elderly regardless of gender. In addition, depression and other mental health problems, as well 
as use of antidepressants, have become widespread worldwide. Both depression and use of 
antidepressants are associated with low bone mineral density (BMD). However, many of these 
results are from cross-sectional studies with small sample sizes. In addition, the mechanism 
underlying the association between depression, use of antidepressants and bone is complicated 
and unclear. The aim of this thesis was to examine, if depression, low subjective well-being (life 
satisfaction) and/or use of antidepressants are associated with lower bone density after taking 
into account several confounding variables. The validity of self-reported antidepressant use was 
evaluated by comparing self-reported data with data from the National prescription register. 
 
Three of the studies utilized data from a cohort of postmenopausal women born between 1932-
41 participating in the large population-based prospective study, The Kuopio Osteoporosis Risk 
Factor and Prevention (OSTPRE) Study. A total of 2 167 women were included in the cross-
sectional study and 1 147 women in the 10-year longitudinal study investigating the association 
between life satisfaction and bone. A total of 1 988 women were included to the 5-year 
longitudinal study investigating the association between antidepressant use and bone loss. In 
addition, 11 031 women were included in the study that explored the validity of self-reported 
use of psychoactive medication. 
 
The remaining two studies utilized adult male population data derived from a similar study, 
the Geelong Osteoporosis Study (GOS) located in south-eastern Australia. A total of 928 men 
(aged 24-98) were included in the cross-sectional study investigating the association between a 
lifetime history of major depressive disorder (MDD), use of antidepressants and BMD. In 
addition 849 men were included in the cross-sectional study exploring the association between 
use of antidepressants and bone quality measured by ultrasound (QUS).  
 
Self-reported life satisfaction (LS) and its improvement were associated with reduced bone loss 
over time in postmenopausal women. Moreover, independent of LS, hospitalization due to 
depression was associated with increased bone loss. Similarly, history of recurrent MDD was 
associated with lower forearm and total body BMD in men.  
 
When studying the use of antidepressants, increased bone loss was seen in women who used 
tricyclic antidepressants and selective serotonin reuptake inhibitors. In addition, accelerated 
VI 
 
 
bone loss was noticed in low weight women or normal weight women who lost weight and 
were using other antidepressants. In the studies with adult men, the negative association 
between use of antidepressants (any) and bone parameters as measured both by QUS and DXA 
were present in men with lighter body weights only as was seen among postmenopausal 
women using other antidepressants. 
 
The study investigating the agreement between self-reported use of psychoactive medication 
and the National prescription register data showed that self-report seems in general to be a 
sufficient indicator for regular use of antidepressants, but prescription register data is better for 
those with irregular use and less severe mental disorders. 
 
The results suggest that both major depression as well as milder psychological symptoms, i.e. 
life dissatisfaction are deleterious to bone health. In addition, the risk of osteoporosis should be 
taken into account when prescribing antidepressants. Prevention of depression, its early 
detection and appropriate medical care are important issues also in the prevention and care of 
lowered bone density in both men and women.  
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TIIVISTELMÄ 
 
Osteoporoosi ja siitä johtuvat murtumat ovat kasvava terveysongelma varsinkin ikääntyneillä 
miehillä ja naisilla. Lisäksi masennus ja muut mielenterveysongelmat sekä niiden myötä 
masennuslääkkeiden käyttö on lisääntynyt kaikkialla maailmassa. Sekä masennuksen että sen 
lääkityksen on todettu vaikuttavan haitallisesti luun tiheyteen. Monet näistä tuloksista ovat 
kuitenkin pienistä poikkileikkaus-aineistoista ja kaikki tutkimukset eivät ole löytäneet yhteyttä. 
Mekanismi masennuksen ja masennuslääkkeen käytön vaikutuksesta luuhun on 
monimutkainen ja epäselvä. Tämän väitöskirjan tavoitteena oli tutkia ovatko masennus, 
tyytymättömyys elämään tai masennuslääkkeiden käyttö yhteydessä alempaan luun tiheyteen, 
ottaen huomioon myös monet sekoittavat tekijät. Ilmoitetun masennuslääkkeiden käytön 
paikkansapitävyys selvitettiin vertaamalla sitä apteekista ostettujen lääkkeiden rekisteriin. 
 
Osa tutkimuksessa käytetystä aineistosta on peräisin vaihdevuosi-iän ylittäneiden naisten 
laajasta kohorttiaineistosta, Kuopion Osteoporoosin vaaratekijät ja ehkäisy -tutkimuksesta, jossa 
postikyselyt ja luuntiheysmittaukset on suoritettu 5 vuoden välein. Elämäntyytyväisyyden 
vaikutusta luuhun selvitettiin poikkileikkaustutkimuksella, johon osallistui 2 167 naista sekä 10-
vuoden pitkittäistutkimuksella, johon osallistui 1 147 naista. Toiseen, masennuslääkkeiden 
käytön vaikutuksia luuhun käsittelevään 5-vuoden seurantatutkimukseen osallistui 1 988 
naista. Lisäksi 11 031 naista otettiin mukaan psyykenlääkkeiden ilmoittamista käsittelevään 
tutkimukseen. 
 
Toinen osa tutkimuksessa käytetystä aineistosta on peräisin Australian Geelongin vastaavasta 
osteoporoositutkimuksesta (Geelong Osteoporosis Study, GOS), jossa mukana oli myös 
miesväestöä. Kaikkiaan 928 miestä (iältään 24-98vuotiaita) osallistui tutkimukseen, missä 
selvitettiin vakavan masennuksen jaksojen sekä nykyisen masennuslääkkeen käytön vaikutusta 
luun tiheyteen poikkileikkaustutkimuksena. Lisäksi 849 miestä samalta ajankohdalta otettiin 
mukaan, kun tutkittiin sen hetkisen masennuslääkkeen käytön vaikutusta luun laatuun 
käyttämällä luunmittauksessa ultraäänimenetelmää. 
 
Elämäntyytyväisyys ja sen paraneminen vähensivät luukatoa vaihdevuosi-iän ylittäneillä 
naisilla. Lisäksi elämäntyytyväisyydestä itsenäisenä, sairaalahoidot masennuksen vuoksi 
lisäsivät luukatoa näillä naisilla. Samalla tavoin usean vakavan masennuksen ajanjakso oli 
yhteydessä alempaan ranteen ja koko kehon luuntiheyteen miehillä. 
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Lisääntynyttä luukatoa oli havaittavissa naisilla, jotka käyttivät trisyklisiä masennuslääkkeitä 
sekä serotoniinin takaisinoton estäjiä. Lisäksi lisääntynyt luukato havaittiin ryhmän ”muut 
masennuslääkkeet” kevyillä sekä normaalipainoisilla käyttäjillä, joilla paino oli pudonnut 
jakson aikana. Samalla tavoin paino vaikutti tuloksiin miesväestöllä ja masennuslääkkeiden 
käytön havaittiin olevan yhteydessä alempaan luuntiheyteen ja ultraäänellä mitattuihin 
luuarvoihin ainoastaan niillä henkilöillä, jotka eivät olleet ylipainoisia. 
 
Tutkittaessa itse ilmoitettujen psyykenlääkkeiden käytön paikkansapitävyyttä, havaittiin sen 
olevan riittävä menetelmä ainoastaan silloin, kun kyseessä on säännöllinen käyttö. 
Rekisteriaineisto on parempi valinta, kun lääkkeen käyttö on epäsäännöllistä tai kun kyseessä ei 
ole vakava sairaus. 
 
Näiden tulosten pohjalta sekä vakava masennus että lievemmät oireet, kuten tyytymättömyys 
elämään näyttäisivät olevan haitallisia luun terveydelle. Lisäksi osteoporoosin riski tulee ottaa 
huomioon masennuslääkkeitä määrätessä. Masennuksen ehkäiseminen, sen havaitseminen ja 
riittävä lääkehoito ovat tärkeitä myös ehkäisemään alentuneen luuntiheyden riskiä sekä 
miehillä että naisilla. 
 
 
Luokitus: QV 77.5, WE 202, WE 250, WM 171.5 
Yleinen suomalainen asiasanasto: luusto; osteoporoosi; luuntiheys; masennus; tyytyväisyys; psyykenlääkkeet; 
SSRI-lääkkeet; paino; vaihdevuodet 
  
IX 
 
 
Acknowledgements 
The present doctoral study was carried out at the Bone and Cartilage Research Unit, Surgery, 
Institute of Clinical Medicine, University of Eastern Finland, Kuopio, during the years 2011-
2015. 
 
I am deeply grateful to Docent of Public Health, Professor Risto Honkanen, MD, PhD, and 
Professor of Psychiatry, Heli Koivumaa-Honkanen, MD, MPH, PhD, for acting as my primary 
supervisors. I thank Risto for his guidance in the development of my thesis and his 
epidemiological and methodological support. I thank Heli for her great ideas, enthusiastic 
support and encouragement during this time. I would like to thank both for their personal 
commitment to my research, the answers to my questions when needed as well as the linguistic 
support.   
 
I want to thank my third supervisor, Professor of Pharmacy Practice, Riitta Ahonen, PhD 
(Pharm), for the opportunity to complete my thesis within the Department of Social Pharmacy. I 
would also like to thank her for the support, help and commitment during my studies. 
 
I would like to thank Professor of Surgery, Orthopaedics and Traumatology, Heikki Kröger, 
MD, PhD, for his positive attitude towards my work, his support and valuable comments made 
during the study. I warmly acknowledge Docent of Obstetrics and Gynecology, Marjo 
Tuppurainen, MD, PhD, for being a co-author on my manuscripts and her valuable comments. I 
would also like to thank Dr Toni Rikkonen, MSc, PhD, for his ideas and comments on the 
methodology. I like to acknowledge and thank the whole OSTPRE group and especially my 
research colleagues Sami Salo and Miika Värri who have shared their ideas and supported me 
during my research. I warmly acknowledge OSTPRE secretarian Seija Oinonen for searching 
and sending me required data, solving statistical problems and helping with the data handling. 
I also thank statisticians Marja-Leena Lamidi and Reijo Sund for the statistical support.  
 
I want to express my gratitude to each of the Geelong Osteoporosis Study researchers at 
Barwon Health and Deakin University, Australia for the opportunity to collaborate. I really 
enjoyed the time spent with you all! I am warmly grateful to my fourth supervisor, Dr Lana 
Williams, MPsych (Clin), PhD, for her collaboration, enthusiastic ideas, linguistic check and 
making the visit to Geelong possible. I would also like to thank Professor of Psychiatry, Michael 
Berk, MMed(Psych), PhD, for collaboration and hosting me, Professor of Epidemiology, Julie 
Pasco, DipEd, PhD, for collaboration as well as her epidemiological, methodological and 
statistical support and Amanda Stuart, BAppSc, for her kind help with the data. 
 
Thank you to Docent of Geriatric Pharmacotherapy, Professor of Family Medicine, Sirkka-Liisa 
Kivelä, MD, PhD, and Professor of Geriatric Medicine, Peter Nordström, MD, PhD, for 
reviewing my thesis and suggested improvements. I also want to warmly acknowledge Docent 
Markku Heliövaara, MD, PhD, for accepting the invitation to be the opponent for the public 
defense of my doctoral thesis. 
X 
 
 
 
I would like to thank all my lovely friends from Kuopio and Veteli who have supported me and 
shared many great times! Special thanks are assigned to my closest friends, Antti Mustonen and 
Topi Koponen, who have enriched my life and given me advice and help whenever needed. In 
addition, I would like to thank my friend Jani Rönkkö who originally informed me of the 
opportunities within the OSTPRE study. 
 
My parents Eliisa and Raimo Rauma are warmly acknowledged for their loving care and 
endless support. Thank you for the excellent basis for my life. Special thanks are also assigned 
to my big sister Tanja Rauma-Pinola, MD, PhD, MSc, for being a great exemplar, her valuable 
comments and lifelong caring. I warmly thank my brother-in-law, Tero Pinola, MD, for his 
encouragement and support during my studies. I also like to thank their wonderful children 
Valtteri, Elmeri, Erika and Oliver for providing me other activities and for all the happy 
moments we have shared. I wish to express my warm thanks to my grandparents, Taimi and 
Veikko Övermark, for their continual support, encouragement and belief in me. 
 
I thank apothecaries Anja Borgmästars and Riitta Visuri-Taipale from Pharmacy of Kaustinen 
and the staff for the possibility to undertake summer work and keeping me updated in the field 
of pharmacy. Finally, I would like to acknowledge the Faculty of Health Sciences (in UEF), 
Finnish Concordia Fund, FinPharma Doctoral Program, Lapland Hospital District, National 
Doctoral Programme of Musculoskeletal Disorders and Biomaterials, North Savo Regional 
Fund of Finnish Cultural Foundation and Saastamoinen Foundation for the personal and/or 
travel grants.  
 
 
 
 
 Kuopio, July 2015 
 
 
 
 Päivi Rauma 
 
  
XI 
 
 
 
List of the original publications 
 
 
 
This dissertation is based on the following original publications: 
 
 
I  Rauma PH, Koivumaa-Honkanen H, Williams LJ, Tuppurainen MT, Kröger HP, 
Honkanen RJ. Life satisfaction and bone mineral density among postmenopausal women - 
Cross-sectional and longitudinal associations. Psychosomatic Medicine. 2014;76(9):709-715. 
 
II  Rauma PH, Koivumaa-Honkanen H, Williams LJ, Tuppurainen MT, Kröger HP, 
Honkanen RJ. Effects of antidepressants on postmenopausal bone loss – A 5-year 
longitudinal study from the OSTPRE cohort. Submitted. 
 
III  Rauma PH, Pasco JA, Berk M, Stuart AL, Koivumaa-Honkanen H, Honkanen RJ, Hodge 
JM, Williams LJ. The association between major depressive disorder, use of 
antidepressants and bone mineral density (BMD) in men. Journal of Musculoskeletal and 
Neuronal Interactions. 2015;15(2):177-185. 
 
IV  Rauma PH, Pasco JA, Berk M, Stuart AL, Koivumaa-Honkanen H, Honkanen RJ, Hodge 
JM, Williams LJ. The association between use of antidepressants and bone quality using 
quantitative heel ultrasound. Australian and New Zealand Journal of Psychiatry. 
2015;49(5):437-443. 
 
V   Rauma PH, Koivumaa-Honkanen H, Kröger H, Tuppurainen MT, Kauhanen J, Honkanen 
RJ. The relationship between self-reported and registry-based data on use of psychoactive 
medications in postmenopausal women. BioMed Central Psychiatry. 2013;13:180-189. 
 
 
The publications are printed with the permission of the copyright owners. 
  
XII 
 
 
  
XIII 
 
 
Contents 
1 INTRODUCTION ……………………………………………………………………………….... 1 
2 BACKGROUND …………………………………………………………………………………... 3 
 2.1 Bone biology …………………………………………………………………………………….. 3 
 2.2 Osteoporosis …………………………………………………………………………………….. 4 
  2.2.1 Diagnostics 
  2.2.2 Epidemiology 
  2.2.3 Risk factors 
  2.2.4 The consequences of osteoporosis - fractures 
 2.3 Depression and antidepressants ………………………………………………………………. 8 
  2.3.1 Epidemiology and biology of depression 
  2.3.2 Antidepressants use and pharmacology  
3 REVIEW OF THE LITERATURE ………………………………………………………………... 11 
 3.1 Depression and bone …………………………………………………………………………… 11 
  3.1.1 The effects of depression on bone biology 
  3.1.2 Population based studies investigating depression and bone  
 3.2 Antidepressants and bone ……………………………………………………………………... 15 
  3.2.1 The effects of antidepressants on bone biology 
  3.2.2 Population based studies investigating antidepressants use and bone 
 3.3 Falls and fractures ………………………………………………………………………………. 18 
  3.3.1 Population based studies investigating depression, antidepressants, falls and fractures 
4 STUDY AIMS AND HYPOTHESES ……………………………………………………………. 19 
5 SUBJECTS AND METHODS ……………………………………………………………………. 21 
 5.1 Study design …………………………………………………………………………………….. 21 
  5.1.1 OSTPRE study (studies I-II and V) 
  5.1.2 GOS study (studies III and IV) 
 5.2 Participants ……………………………………………………………………………………… 22 
 5.3 Data collection …………………………………………………………………………………... 23 
  5.3.1 Postal enquiries 
  5.3.2 Life satisfaction (studies I and V) 
  5.3.3 Major depressive disorder (studies III and IV) 
 5.4 Clinical measurements …………………………………………………………………………. 25 
  5.4.1 Bone measurements 
  5.4.2 Other measurements 
 5.5 Registration data ……………………………………………………………………………....... 25 
  5.5.1 The National prescription register (studies I, II and V) 
  5.5.2 Other registers (studies I, II and V) 
  5.5.3 Socio-economic status (studies III and IV) 
 5.6 Statistical analyses ……………………………………………………………………………… 27 
6 RESULTS …………………………………………………………………………………………… 29 
 6.1 Characteristics of the study populations …………………………………………………….. 29 
 6.2 Life satisfaction and bone loss in postmenopausal women (Study I)…………………….. 30 
XIV 
 
 
  6.2.1 Cross-sectional associations 
  6.2.2 Longitudinal associations 
 6.3 Antidepressant use and bone loss in postmenopausal women (Study II) ……………….. 32 
 6.4 Major depressive disorder (MDD), use of antidepressants and BMD in men (Study III).. 33 
  6.4.1 Cross-sectional associations between MDD and BMD 
  6.4.2 Associations between use of antidepressants and BMD 
 6.5 Use of antidepressants and bone quality in men (Study IV) ………………………………. 34 
 6.6 Validation study on self-reported psychoactive medication use (Study V) ……………… 35 
7 DISCUSSION ……………………………………………………………………………………… 37 
 7.1 The association between mental health and bone measurements ………………………… 37 
 7.2 The association between use of antidepressants and bone ………………………………… 38 
7.3 Validity of self-reported psychoactive medication use ……………………………………. 40 
7.4 Strengths and limitations ……………………………………………………………………… 42 
8 CONCLUSIONS …………………………………………………………………………………... 43 
9 RECOMMENDATIONS …………………………………………………………………………. 45 
10 REFERENCES …………………………………………………………………………………….. 47 
 
 
 
APPENDICES: 
 
APPENDIX I 10-YEAR POSTAL ENQUIRY 
 
ORIGINAL PUBLICATIONS (I-V) 
 
  
XV 
 
 
Abbreviations 
 
5-HT  5-hydroxytryptamine; serotonin 
5-HTT  5-HT transporter 
ATC  Anatomical-therapeutic-chemical 
BMD  Bone mineral density 
BUA  Broadband ultrasound attenuation 
BMI  Body mass index 
CI  Confidence interval 
DA  Dopamine 
DDD  Defined daily dose 
DXA  Dual x-ray absorptiometry 
GLM  General linear model 
GOS  Geelong Osteoporosis Study 
HT  Hormone therapy 
LS  Life satisfaction 
MAOI  Monoamine oxidase inhibitor 
MDD  Major depressive disorder 
NA  Noradrenaline 
OR  Odds ratio 
OSTPRE  Osteoporosis Risk Factors and Prevention Study 
QUS  Quantitative ultrasound 
SD  Standard deviation 
SI  Stiffness index 
SOS  Speed of sound 
SNRI  Serotonin and norepinephrine reuptake inhibitor 
SPSS  Statistical package for social sciences 
SSRI  Selective serotonin reuptake inhibitor 
TCA  Tricyclic antidepressant  
XVI 
 
 
 
 
 
 
 
1 Introduction 
Osteoporosis i.e. low bone mineral density (BMD) has become a public health problem because 
of aging populations. The worldwide proportion of older adults aged 60 or older has risen from 
8% in 1950 to 11% in 2009 and with an expectation of 22% by 2050 [1]. In Finland, this 
percentage is now already 26% [2].  Bone mass decreases with age and especially in estrogen-
deficient women after menopause. It has been estimated that about 300 000 persons aged 50 and 
over suffered from osteoporosis and approximately 36 000 new fragility fractures were 
sustained in Finland in 2010 [3]. Of all these fractures, hip fractures constitute of over 6 500 and 
about 70% of them occur to women [3]. Hip fracture often requires long-term hospitalization, 
can lead to reduced state of health and increase the risk of mortality. Ageing of population 
means that additional amount of health care resources is required worldwide because of the 
increasing occurrence of osteoporosis. Prevention and good management of osteoporosis could 
decrease the rate of hip fractures by 25-50% and also save a vast amount of economic resources 
[4].  
 
Depression is also a common public health problem and one of the leading causes of disease 
burden worldwide [5]. The 1-year prevalence of major depressive disorder was over 7% among 
the Finnish adult population in 2011, being twice more common in women than in men [6]. 
Even if the use of antidepressants has doubled during the last decade [7], less than half of the 
depressed individuals can been detected in primary care [8]. Correct identification is lower in 
older than younger adults [8]. 
 
The Bianchi et al. [9] study found that 42% of postmenopausal women with osteoporosis have 
depressive mood states, regardless of occurrence of fractures. Several epidemiologic and clinical 
studies suggest a connection between depression, use of antidepressants (especially selective 
serotonin reuptake inhibitors (SSRI)) and bone health. Results are similar both among males 
and females and regardless of age. However, not all studies have found an association and 
majority are cross-sectional. The use of any antidepressants as an entire group or use of tricyclic 
antidepressants (TCA) has been studied less with contradictory results. In addition, studies 
have concentrated mostly on clinically diagnosed depression or depressive symptoms as a 
dichotomous variable. 
 
There may be several potential pathways used to explain the association between depression or 
antidepressant use and bone health. Depression may influence BMD and fracture risk through 
both physiologic and behavioral mechanisms, and affect for example cortisol and catecholamine 
metabolism [10]. In addition, antidepressants may affect bone cells directly [11]. However, the 
associations between depression and use of antidepressants on bone still remain unclear and 
may be confounded by lifestyle and other medications and diseases. 
 
The aim of the present study was to examine cross-sectionally and longitudinally, whether 
depression, low subjective well-being (life satisfaction) and/or use of antidepressants are 
2 
 
 
associated with osteoporosis, after taking into account for example lifestyle, comorbidity and 
other medications. By using two large population-based cohorts, the Kuopio Osteoporosis Risk 
Factor and Prevention (OSTPRE) Study from Finland and Geelong Osteoporosis Study (GOS) 
from Australia, it was able to study these relationships both in postmenopausal women 
(OSTPRE) and in adult men (GOS). 
 
Chapter 2 presents biological, clinical and epidemiologic background for this thesis and chapter 
3 presents the literature review of the studies on the relationships between depression and 
antidepressant use and bone health. The review is focused on clinical and epidemiological 
studies of postmenopausal women, which is the other main population group in this thesis. 
Thereafter, Aims and hypotheses (chapter 4), Subjects and methods (Chapter 5), Results 
(Chapter 6), Discussion (Chapter 7), Conclusions (Chapter 8) and Recommendations (Chapter 9) 
are presented. 
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2 Background 
2.1 BONE BIOLOGY 
Bone is a living tissue consisting of cells and an extracellular matrix [12, 13]. It becomes 
mineralized by deposition of calcium hydroxyapatite which gives bone its rigidity and strength 
[12]. The reticulate structure of cancellous bone gives it also flexibility. Bone regenerates 
throughout life with the fastest growth period before the age of 20-30 years [13].  
 
Bone contains four different cell types: osteoblasts, osteoclasts, osteocytes and bone-lining cells 
[13]. Osteoblasts are bone forming cells synthesizing collagen to form non-mineralized bone 
matrix (osteoid) and participating in osteoid calcification [13]. Osteoclasts are bone resorbing 
cells. Osteocytes are mature osteoblasts embedded within the bone matrix [12]. They act as 
mechanosensors and communicate with other bone cells with biochemical signals. Bone-lining 
cells are resting osteoblasts which form a cell layer as a cover on the formed bone [13]. 
 
In bone remodeling, osteoclasts resorb bone tissue which is then rebuilt by osteoblasts (Fig 1). 
The resorption process takes 2-4 weeks but rebuilding several months [14]. Under normal 
conditions, resorption and formation processes are tightly coupled following each other [12, 14]. 
Remodeling is needed to repair the altered bone mass-structure-strength configuration after 
changes e.g. in work load, physical activity or health status [13, 15]. Age-related bone loss is 
started already in the ages of 20-30 years when bone resorption becomes greater than formation 
and bone remodeling cycle remains negative [13, 16]. This leads to bone loss of about 0.5-1% per 
year. Bone metabolism may also be disturbed in some diseases and metabolic disturbances [17]. 
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Figure 1. A simplified picture of bone remodeling process including resorption i.e. removing old bone 
tissue by osteoclasts and new bone formation by osteoblasts. Reproduced with permission of the 
American Society for Bone and Mineral Research (Riggs BL and Parfitt AM, J Bone Miner Res 
2005;20:177-184) [14]. 
2.2 OSTEOPOROSIS 
2.2.1 Diagnostics 
Osteoporosis is a skeletal disorder associated with reduced bone mass and mineral density and 
increased risk of fractures. Using bone measurements the changes in bone and fracture risk can 
be assessed and intervention decisions made [18]. The most common BMD measurement is dual 
X-ray absorbtiometry (DXA) [19]. It scans the bone mineral content since X-rays are sensitive for 
calcium in the tissue and report it as areal density (g/cm2) [19]. The most often measured sites 
for DXA are lumbar spine (L1-L4) and proximal femur (femoral neck and total hip) but also 
forearm (mid and ultradistal radius) and total body measurements are used [18] (Fig 2). A 
strong association between DXA measurement results and fracture risk has been widely 
reported [20, 21]. 
 
World Health Organization (WHO) has introduced the criteria for osteoporosis using the DXA 
[19]. Osteoporosis was determined as a bone density T-score of 2.5 standard deviations (SD) or 
more below the mean of healthy young (20-40 years) white adult women [22] (Fig 2). 
Osteopenia, a milder form of low bone density, is present when T-score is between -1 and -2.5 
[18]. 
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Figure 2. DXA proximal femur measurements from OSTPRE data. YA; young adults. 
 
In addition to bone density, bone strength can also be expressed by bone quality. It includes 
bone architecture, damage accumulation (e.g. microfractures) and mineralization [22]. 
Quantitative ultrasound (QUS) measures bone quality and can be used for measurements at 
peripheral skeletal sites, for example at the heel [18]. It includes the determination of Broadband 
Ultrasound Attenuation (BUA; dB/MHz) reflecting bone density and architecture, Speed of Sound 
(SOS; m/sec) reflecting bone density and elasticity and Stiffness Index (SI; %) a combination of BUA 
and SOS. QUS might be a reasonable alternative to BMD scans and performing characterization 
measurements [23, 24]. Compared to DXA, QUS devices are less expensive, faster, without 
ionizing radiation and easier applicable equipment at all levels of clinical settings [25]. In 
addition, QUS measures parameters of bone that are not detected by DXA. Using QUS, for 
example, health centers and pharmacies could provide indicative bone measurements for 
osteoporosis more widely than by using DXA alone [26]. QUS is also shown to predict fractures 
in women and men [27]. 
 
Less frequently used bone density and composition measurements are quantitative computed 
tomography (QCT) from spine and peripheral QCT (pQCT) from forearm. QCT and pQCT 
measure bone 3-dimensionally (3D) and provide knowledge of geometric and structural 
parameters as total, cortical or cancellous BMD [18]. 
2.2.2 Epidemiology 
More than 75 million people suffer from osteoporosis worldwide and the risk is significant in all 
ethnic groups [19]. In Finland, it is estimated that 6.4% of men and 21.5% of women aged 50 
years or older suffered from osteoporosis in 2010 [3]. The rates are similar all over Europe, 
which means almost 28 million people suffering from it [28]. This is true also for example in the 
Australian adult population, where the rates are approximately 6% for men and 17% for women 
[29]. In addition, about 40% or more of men and women aged over 50-years have lowered bone 
mass [29]. 
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Osteoporosis is an underdiagnosed and undertreated disease [30]. However, screening of the 
whole ageing and postmenopausal population is not possible, with targeted intervention more 
likely [31]. A study from Australia showed that more than 75% of those at increased risk of 
osteoporosis have not undergone investigation [30]. A Finnish study also showed a large 
difference between self-reported physician-diagnosed and measured prevalence of 
osteoporosis: only 0.9% of men aged 30 years and over reported it as diagnosed, while T-scores 
from estimated BMD values using QUS measurement gave a prevalence of 2.7% [32]. For 
women these proportions were 4.1% and 8.5%, respectively. In men over 55 year, the diagnosed 
proportions varied from 1.1% to 4.2% increasing with age whereas measured proportions 
varied from 2.6% to 14.7%, respectively. In women the rates were 5.1-17.0% and 7.1-62.8%, 
respectively. Differences between diagnosed and measured values increased with age. 
2.2.3 Risk factors 
Osteoporosis can be roughly divided into primary or secondary osteoporosis. Primary 
osteoporosis is caused by genetic or hormonal factors, while secondary osteoporosis is due to 
diseases and medications [22]. In addition, physical inactivity, smoking and nutritional factors - 
including alcohol – may increase osteoporosis risk at any age. Postmenopausal osteoporosis is 
derived mostly by primary causes, whereas osteoporosis in men and perimenopausal women is 
more often due to secondary causes [22]. There are several risk factors to influencing bone loss 
and osteoporosis across all ages independent of gender (Table 1). 
 
Table 1. Risk factors of osteoporosis. 
 
 age and gender 
 family history of osteoporosis / fractures 
 low energy fracture history 
 low weight 
 physical inactivity 
 low calcium and vitamin D intake 
 smoking 
 major alcohol consumption 
 early menopause 
 diseases: e.g. anorexia, intestinal diseases (crohn´s disease, colitis ulcerosa, celiac disease, lactose 
intolerance), liver diseases, kidney diseases (uremia, idiopathic hypercalciuria), type 1 diabetes,  
hormonal diseases (hypogonadism, hyperthyroidism, hyperparathyroidism, hyperprolactinemia, 
cushing´s disease), rheumatoid arthritis, myeloma, bone cancers, stroke, depression 
 medication: e.g. corticosteroids, antiepileptic medication (phenytoin, carbamazepine), antihormone 
therapy (aromatase inhibitors, antiestrogens, antigonadotropins), high doses of thyroxine, cytostatics, 
heparine, litium, loop diuretics, antidepressants  
 
Depending on age and gender, loading of the body increases bone mass: high body weight and 
activity are the main factors increasing bone strength [33-35]. Physical exercise, particularly 
sports where skeleton gets jolts and twisting is beneficial for bone. Behavioral and nutritional 
factors play an important role in bone metabolism [36]. Bone needs calcium and phosphate as 
building materials and vitamin D is essential for example in improving calcium absoption [37]. 
However, poor lifestyle such as smoking [38] and heavy use of alcohol [39] have been shown to 
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decrease BMD. The genetics of osteoporosis can explain even approximately 60-80% of variation 
in bone density [40]. 
 
Hormonal factors are important in prevention of osteoporosis: lack of testosterone or estrogen 
are risk factors for bone loss as well as low estrogen production related to amenorrhea, irregular 
menstruation and early menopause (before the age of 45) in women [41, 42]. The increased 
overactivity of thyroid, parathyroid, pituitary or adrenal gland can result in increased 
corticosteroid secretion or have a negative effect, for example, to menstruation [43, 44]. Insulin 
stimulates bone formation and remodeling and its deficiency in diabetes decrease bone density 
[45, 46]. The inflammation markers of arthritis and its cortisone therapy can dissolve and 
deteriorate bone but disease itself can also decrease bone strength via avoidance of physical 
activity [47]. Stroke may cause paresis, disability and reduced mobility, but also nutritional and 
iatrogenic factors may play a role in stroke as an osteoporosis risk factor [48]. And one of the 
most important factors, diseases related to eating or absorption of food or calcium, or diseases 
accelerating calcium elimination, affect bone negatively [44] 
 
In addition to diseases, there is a large number of medicines known to affect bone. They can 
affect for example the absorption or metabolism of calcium, phosphate or vitamin D [44], as is 
the case with phenytoin and carbamazepine, which accelerate vitamin D elimination or with 
corticosteroids [44], which prevent intestinal calcium absorption [49]. Corticosteroids affect 
bone also directly by increasing calcium reabsorption from the bone and secretion but also by 
preventing the function of osteoblasts [49]. Cytostatics (used in the treatment of prostate and 
breast cancer) can decrease androgen and estrogen production and in turn decreases bone 
density [44]. High doses of thyroxine increase the negative regulation of bone metabolism and 
negative calcium balance similarly as hyperthyroidism [50]. Due to different mechanisms, loop 
diuretics have been shown to affect bone negatively whereas thiazide diuretics has been found 
to be positively associated [51]. Some other medicines have also been shown to affect bone 
negatively - directly or indirectly [44]. 
2.2.4 The consequences of osteoporosis - fractures 
Osteoporotic bone, which is more prevalent in older people, is more vulnerable and weaker 
than normal bone and therefore even low-energy force can cause fractures [19]. It is estimated 
that approximately 9 million fractures, including 1.6 million hip fractures are caused by 
osteoporosis annually around the world [19]. In 2010, approximately 36 000 new fragility 
fractures occurred among those aged 50 years and older in Finland [3]. Of all fractures in 
Finland, hip fractures constitute over 6 500 [3]. The incidence of fractures varies by age, gender 
and ethnicity as does osteoporosis [22]. Postmenopausal Caucasian women, experience the 
highest age-adjusted incidence of hip fracture, with three out of four occurring in this group [22, 
52].  
 
Osteoporotic fractures are associated with increased risk of other physical consequences and in 
difficulties in activities of daily life [22]. Hip fracture is the most serious fracture, because it 
often requires long-term hospitalization. This can lead to reduced state of health and mortality, 
in particular amongst older people [53, 54]. Only one third of hip fracture patients returns to pre 
fracture level of function and one third require placement in a nursing home [22]. Even though 
8 
 
 
women have a higher risk of osteoporosis and fractures, men suffer from more adverse 
outcomes, for example a 2-fold higher mortality risk than women [55, 56]. Overall, patients with 
hip fracture have a 5- to 8-fold increased all-cause mortality during the first three months [56]. 
 
Additional amount of health care resources are required because of the increasing occurrence of 
osteoporosis and its consequences. The costs of fractures in the European Union have been 
estimated to be 37 billion Euros in 2010 with an expectation for increase of 25% by 2025 [28]. In 
Finland the cost of fractures was 383 million Euros in 2010 [3]. The majority of costs are derived 
from long-term hospitalization and patient rehabilitation following fracture [22]. Prevention 
and good management could decrease the rate of hip fractures by 25-50% and save a vast 
amount of economic resources [4]. 
2.3 DEPRESSION AND ANTIDEPRESSANTS  
2.3.1 Epidemiology and biology of depression 
Depression is a disease with significant neurobiological abnormalities involving structural, 
functional and molecular changes in several areas of the brain [57]. These changes include for 
example high level of the stress hormone cortisol, hypothalamic overactivity, increase in pro-
inflammatory cytokines and low levels of monoamines, particularly serotonin (5-
hydroxytryptamine, 5-HT) and noradrenaline (NA) which are all associated with depression 
[57]. Depression is often chronic and recurrent but also a progressive illness [57].  
 
Depression is one of the leading causes of disease burden in the world [5]. It is estimated that 
almost 100 million individuals suffered from depression worldwide in 2004 and 5 million of 
them were over 60 years of age [5]. The 12-month prevalence of major depression was estimated 
to be 6-7% in European Union in 2011 [58]. Depression is twice as common in women compared 
to men and its incidence peaks again after menopause [59, 60]. The lifetime prevalence for 
depression and mood disorders can be as high as 20% [61]. However, the disease is still 
underdiagnosed and -treated [8, 58]. It has been estimated that less than half of all depressive 
cases receive any treatment indicating the high level of unmet needs [8]. 
 
In addition to diagnosed major depressive disorders (MDD), milder depressive symptoms, 
subthreshold depression as well as life dissatisfaction are common. According to Vaillant [62], 
subjective well-being, indicated by life satisfaction and happiness, is one of the main 
dimensions of mental health. Life dissatisfaction, measured with four self-reported items, can 
be used to identify in a general population those with various long-term adverse somatic and 
mental health outcomes [63-67]. Even if life dissatisfaction is closely related to several indicators 
of poor mental health [64], it is also strongly linked with depression both in the general 
population [68, 69] and in psychiatric patients [64] in cross-sectional and longitudinal studies.  
 
Research on depression and mental health is important, because, in addition to depression itself 
and its consequences, psychological factors can be involved in developing, recovery and health 
promoting processes in chronic somatic illness [70, 71] such as cardiovascular disease [72-74] 
and cancer [75]. 
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2.3.2 Antidepressants use and pharmacology  
Together with depression, use of antidepressants has increased rapidly during the past two 
decades all over the world [7, 76]. Approximately 8% of Europeans [77], 9% of Australians [7] 
and 11% of Americans [76, 78] use antidepressants, making it the most commonly used 
medication group between 2005 and 2008 among Americans aged 18-44 [76]. In Finland the 
consumption of antidepressants has been doubled in 2000-2010 [79], and nowadays about 7% of 
the Finns use antidepressants (Fig 3). The most used antidepressants are selective serotonin 
reuptake inhibitors (SSRI). 
 
In addition to depressive disorders, already a half of all antidepressants are nowadays 
prescribed for other indications, i.e. anxiety and other psychiatric (e.g. sleep disorders) or non-
psychiatric (e.g. musculoskeletal conditions, chronic pain, migraine headaches) conditions [80, 
81]. In particular, over half of all tricyclic antidepressants (TCAs) are now used for neuropathic 
pain or sleep disorders [80, 81]. In respect to SSRIs the use for anxiety is increasing [80, 81]. 
 
 
Figure 3. Consumption of antidepressants between 1995-2013 in Finland [79]. Abbreviations: DDD, 
defined daily dose; MAO-A I, monoamine oxidase A inhibitor; Other AD, other antidepressants (see Table 2). 
SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant. 
 
The Anatomical Therapeutic Chemical (ATC) codes classify medicines mainly according to 
mode of action (Table 2) [82]. Binding affinity to transporters and receptors varies also within 
the groups [83]. The main target of the treatment with antidepressants is to normalize low 
neurotransmitter, 5-HT and NA levels in the synapses [57]. 
 
For example blocking the serotonin transporter (5-HTT) inhibits the serotonin reuptake. This 
leads to higher levels of serotonin in the synapses, prolonging of the serotonin receptor 
activation and increasing the impact in postsynaptic neurotransmission [83-85]. 
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Table 2. Antidepressant subgroups and the mechanism of the effect [57, 82, 83, 86].  
 
Antidepressant subgroup ATC-code Mechanism of effect 
Non-selective monoamine 
reuptake inhibitors (i.e. tricyclic 
antidepressants; TCA) 
N06AA Inhibit 5-HT and NA reuptake.  
 
Block also -adrenergic, histamine and muscarine 
receptors. 
Selective serotonin reuptake 
inhibitors (SSRI) 
N06AB Inhibit mainly only 5-HT reuptake. 
Monoamine oxidase (MAO) 
inhibitors, non-selective 
N06AF Inhibit both isoentzyme A (MAO-A) and isoentzyme B 
(MAO-B) -> inhibit the metabolism of 5-HT, NA and 
dopamine (DA) -> higher extracellular levels of these 
compounds. 
Monoamine oxidase A (MAO-A) 
inhibitors, selective 
N06AG Inhibit selectively MAO-A. 
Other antidepressants N06AX Effect differs according to active substance. 
 
E.g. mirtazapine blocks 5-HT2, 5-HT3, 2-adrenergic and 
histamine receptors and act as agonist for 5-HT1 receptor 
but does not affect monoamine reuptake. 
Abbreviations: 5-HT, serotonin; ATC, anatomical-therapeutic-chemical; NA, noradrenaline. 
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3 Review of the literature 
Epidemiologic and clinical studies have shown a connection between depression, 
antidepressants and skeletal effects, including fractures and falls [10, 87]. However, the 
connection is unclear and there may be several potential pathways. Depression might influence 
BMD and fracture risk through both physiologic and behavioral mechanisms, despite the use of 
the antidepressant medication (Fig 4). In addition, other health disorders, lifestyle factors and 
certain medications influence BMD and need to be taken into account. 
 
Biological
  Cortisol
   Inflammation
   Catecholamines
   Gonadal steroids
Behavioral
  Smoking
   Physical activity
   Alcohol abuse
Confounders
   Comorbid medical conditions
   Medication use
Anti-depressant
medication use
Depression
Bone mineral density
Falls FallsFractures
 
 
Figure 4. Putative pathways between depression and osteoporosis. Adapted with permission of the 
International Osteoporosis Foundation and National Osteoporosis Foundation (Mezuk et al. 
Osteoporos Int. 2008;19:1-12) [10]. 
3.1 DEPRESSION AND BONE 
3.1.1 The effects of depression on bone biology 
The association between depression and osteoporosis is two-directional and several factors 
seem to be involved factors (Fig 5). Osteoporosis and resultant fractures can lead to long-term 
hospitalization or resting time causing physical inactivity through impaired ability to move. 
These as well as chronic pain are risk factors for depressive symptoms and diminished quality 
of life. Depression can contribute to osteoporosis in several ways: depressive patients often 
possess poor lifestyle, including for example physical inactivity, smoking, heavy alcohol 
consumption, low calcium and vitamin D intake and reduced exposure to sunlight [88]. In 
addition to lifestyle factors, depression itself affects neurotransmitters which promote 
development of low BMD. 
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Figure 5. Associated factors between depression and osteoporosis. Adapted with permission of the 
journal of Hormones (Aloumanis K and Mavroudis K. Hormones 2013;12(3):350-362) [88]. 
Abbreviations: SNS, sympathetic nervous system. 
 
Depression seems to affect cortisol and catecholamine metabolism also. Indeed stress effects are 
partly mediated by corticosteroid hormones [89] even if the relationship between depression 
and hypercortisolism is complicated [90-92]. Based on mouse models chronic stress seems to 
cause increased skeletal noradrenaline and serum cortisol levels which are associated with bone 
loss [93]. It has been suggested that this effect is caused via the hypothalamic-pituitary-adrenal 
(HPA) axis [87, 93]. Noradrenaline metabolism is also disturbed in depression [94].  
 
Population studies have shown an association between depression and increased levels of bone 
resorption markers (including parathyroid hormone) [95-98] and proinflammatory cytokines 
[99] as well as decreased levels of bone formation markers (including osteoprotegerin) [95, 97, 
100] and anti-inflammatory cytokines [99]. Also increased plasma cortisol levels or urinary 
cortisol excretion [97, 100] and lower 25-hydroxivitamin D [95] in depressive patients have been 
reported. In contrast, some studies have found no association between depression and bone 
remodeling factors [101, 102], increased cortisol levels [95, 98, 102] or low urinary excretion 
levels of some bone resorption markers [100].  
 
Fat tissue and its adipocytes are responsible for circulating hormones. Adipocytes secrete for 
example leptin, which is involved in stimulating food intake and energy expenditure [103]. 
Obese people are more likely to have depression than non-obese [104], but the association 
between leptin levels and risk of depression is not clear [105, 106]. Circulating leptin may also 
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play a role in regulating bone mass, even if its associations with bone have been controversial 
[107-109]. This association may be due to, for example, the effect of neuronal transmitters, such 
as serotonin. Hyperserotoninemia has been shown to reduce plasma leptin levels [110] but it 
has also been reported that certain antidepressant therapy (i.e. serotonin transporter blockade) 
increase those levels [111]. The reason why serotonin affects leptin levels can partly be 
explained by serotonin receptors and transporters which have been found expressed in 
adipocytes [110]. In addition, low gonadal hormone levels are associated with depression [90] 
and may decrease BMD also via this pathway [98]. 
 
Taken together, the association between depression and BMD is complicated and is suspected 
to be a result of many factors. In addition to lifestyle, neuronal transmitters and other factors 
associated with depression, antidepressant medication may as well partly explain the deficits in 
BMD seen among those with depression. 
3.1.2 Population based studies investigating depression and bone 
The association between depression or depressive symptoms and bone density has not been 
completely established, even though several studies have found a negative association (i.e. 
depression associated with bone loss). There are also many studies that have reported no 
association. However, none of the studies has found a significant positive association between 
depression and BMD. A causal role for depression in the pathogenesis of osteoporosis has 
rarely been studied. The associations between depression or depressive symptoms and bone 
among postmenopausal women are shown in Table 3 and larger meta-analyses shown in Table 
4. 
 
Table 3. The studies regarding association between depression or depressive symptoms and bone 
parameters among postmenopausal women. 
 
Study Design N/ used 
diagnostic method 
Studied variable Association 
Atteritano et al. [95] cross-sectional 
 
50 MDD patients 
(DSM-IV), 50 
controls 
Spine, femoral BMD (DXA), 
calcaneal, phalanges US 
(ultrasonography) 
negative * 
Diem et al. [112] longitudinal 
(~4.4-year) 
4 177, GDS a Femoral bone loss (DXA) negative * 
Erez et al. [113] cross-sectional 135, SRDS a Spine, femoral BMD (DXA) negative * 
Laudisio et al. [114] cross-sectional 187, GDS a T-score, Z-score and SI (US) no assoc. 
Oh et al. [115] cross-sectional 510, K-BDI a T-score, Z-score and SI (US) no assoc. 
Spangler et al. [116] cross-sectional 
and longitudinal 
(3-year) 
~4 500, Burnam´s 
scale - a short 
version of CES-D a 
Spine, femoral, total body 
bone loss (DXA) 
no assoc. 
Tolea et al. [117] cross-sectional, 
longitudinal    
(7-year) 
1 350, CES-D a newly diagnosed osteoporosis negative * 
Whooley et al. [118] cross-sectional 7 414, GDS a Spine, femoral BMD (DXA) no assoc. 
Abbreviations: CES-D, the Center for Epidemiologic Studies Depression Scale; DSM-IV, Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition; GDS, Geriatric Depression Scale; K-BDI, Korean version of Beck 
Depression Inventory; MDD, major depressive disorder; SI, stiffness index; SRDS, Zung Self-Rating Depression 
Scale; US, ultrasound. a Higher score indicates the more severe depression. * Depression had detrimental effects to 
bone. 
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Studies including premenopausal women [96-99, 102, 119-121], adolescents [101, 122, 123] and 
women across the wider age range [100, 124-128] have been conducted with majority finding an 
association between depression or depressive symptoms and low BMD [96-100, 123, 124, 126, 
128, 129]. However, not all studies have found an association [101, 102, 119-122, 125] nor has it 
been seen at all bone sites [123, 124, 126]. Also weight has been shown to affect results [127]. As 
to longitudinal studies, no association between depression and bone has been found among 
other women groups than postmenopausal [112, 122, 127].  
 
Most of the cross-sectional studies including men have also found a negative association between 
depression or depressive symptoms and bone [101, 114, 119, 120, 127, 130-132] but again, not all 
[122, 126, 133] nor all bone sites [132]. One longitudinal study among men has reported a 
negative association [130] but not all [122, 127, 133]. These studies have been carried out among 
older men [114, 130, 132, 133], young adults [119, 120], adolescents [101, 122] and others 
including a wider age range [126, 127, 131]. Studies on both genders with populations aged over 
40 years have found depression to be negatively associated with bone [134-136]. The association 
has been shown to be stronger in studies including patients with major depression than in 
studies on persons with depressive symptoms in both men and women [96, 119, 123, 126, 129]. 
 
Table 4. Meta-analyses of the association between depression / depressive symptoms and BMD. 
 
Study Design Outcome 
Cizza et al. [137] Included 20 articles 
with BMD results  
Lower mean BMDs in depressive subjects vs. controls: 
    - 4.7% lower at the spine  
    - 3.5% lower at the total hip  
    - 7.3% lower at the femoral neck 
Wu et al. [138] Included 13 articles 
with BMD results 
Lower mean BMDs in depressive subjects vs. non-depressed: 
    - 0.053 g/cm2 (5.9%) lower at the spine  
    - 0.052 g/cm2 (6.0%) lower at the hip 
Among participants with severe depression vs. non-depressed:  
    - 0.074 g/cm2 lower at the spine  
    - 0.080 g/cm2 lower at the hip 
The association was strongest in premenopausal women. 
Yirmiya et al. 
[139] 
Included 22 articles 
with BMD results 
Depressed had lower BMD than non-depressed: 
    - Diagnosed by a psychiatrist -> clearly evident 
    - Self-reported -> hardly any association 
The association was strongest in premenopausal women. 
 
The associations with other mental health problems such as milder mood symptoms, anxiety or 
stress with bone health have been investigated rarely with some results reporting that they are 
also deleterious to bone. Associations between stress and low BMD have been found in 
postmenopausal women [113]. Oikonen et al. [140] showed that depressive symptoms increased 
risk of lower BMD only in those men who suffered from severe work-related stress. Long-term 
mental distress has been investigated also by Søgaard et al. [141] but they found no association 
with BMD, however distress was associated with increased fracture risk. Mood disorders are 
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associated with lower bone quality values among men and younger women but not among 
older women [142]. Also anxiety has been found to have a negative association with bone in 
men [127, 142] and in postmenopausal women [113] but this association was not found in all 
studies of women [127, 142]. To date, there are no previous studies on the association between 
well-being and BMD. 
3.2 ANTIDEPRESSANTS AND BONE 
3.2.1 The effects of antidepressants on bone biology 
Antidepressants vary in their mechanism of action and can inhibit selectively or unselectively 5-
HT and NA reuptake (i.e. block transporters), inhibit the metabolism of 5-HT, NA and 
dopamine (DA), block -adrenergic, histamine and muscarine receptors and/or act as an agonist 
for the 5-HT1 receptor (see Chapter 2.3.2). 
 
Studies have shown that these neurotransmitters are also associated with bone metabolism 
(Table 5). Serotonin, for example, is an important neurotransmitter in the brain but also in 
gastrointestinal signaling where it is mostly synthesized (~95%) [143]. It has also been shown to 
participating in bone metabolism [85, 144]. The source of 5-HT used by bone cells is still unclear, 
with some studies showing that these cells are able to produce 5-HT themselves [85]. By 
blocking 5-HT transporters, antidepressants can influence bone cell activities. 
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Table 5. Examples of the effects of neurotransmitters on bone. 
 
Neurotransmitter The effect on bone 
Serotonin (5-HT) Both 5-HT receptors and 5-HT transporters (5-HTT) have been found in osteoblasts, 
osteoclasts and osteocytes -> take 5-HT into the bone cells. 
 
1. Involved in bone formation and resorption processes:  
- SSRIs are shown to directly inhibit human osteoclast and osteoblast formation and 
function [11] 
- SNRI treatment -> increased levels of the bone resorption marker has been 
reported with a population study [145] 
- SSRI treatment or null mutation 5-HTT gene -> detrimental effects on bone mineral 
accrual in mice models [146] 
 
2. Opposite effects on bone mass depend on its origin:  
- Gut-derived circulating 5-HT inhibits osteoblast proliferation via serotonin receptors 
-> decrease in bone formation [147] 
- Central 5-HT inhibits sympathetic output, which otherwise negatively controls bone 
formation and favors bone resorption -> enhance bone mass [147] 
 
3. Contrasting evidence of serotonin signaling and its effects on bone cells [85, 144]: 
- SSRI treatment has been associated with bone formation in mice but not in 
estrogen-deficient animals [148] -> support the hypothesis of estrogen-deficiency 
after menopause as promoting bone loss among the antidepressant users 
Noradrenaline (NA) Adrenoreceptors [149, 150] and NA transporters (NET) [151] are expressed in 
osteoblasts.  
 
1. Receptors associated both bone formation and resorption processes [149, 150]: 
- 1B-adrenoreceptors, which are also target of TCAs, are involved in osteoblast 
proliferation [149, 152] 
- 2-adrenoreceptors are associated with bone resorption [153, 154] -> blocking the 
2-adrenoreceptors leads to higher bone density [93, 155] 
 
2. Controversial studies, i.e. accelerated bone loss both: 
- With increased NA levels [93, 155] 
- After pharmacological NET blockade or genetic ablation of NET in vivo [151] 
Dopamine (DA) Receptors have been found in osteoclast precursors [156]. In addition, active DA system 
has been found in bone marrow cells [157]. 
 
1. DA inhibits osteoclast formation and differentiation via D2-like receptor signaling [156]. 
 
2. High risk of osteoporosis is associated both with: 
- Parkinson´s disease, where DA levels are low [158] 
- Schizophrenia patients taking D2-like receptor antagonists [159, 160] 
 
3. DA transporter deficient mice is shown to have lower bone mass and strength [161]  
Histamine Receptors have been found in osteoblasts and osteoclasts [162-164]. 
 
1. Histamine acts directly on osteoclasts, osteoclast precursors and osteoblasts  -> 
promotes the development and expression of osteoclasts [162-164].  
Abbreviations:  5-HT, serotonin; 5-HTT, serotonin transporter; DA, dopamine; NA, noradrenaline; NET, 
noradrenaline transporter; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin 
reuptake inhibitor; TCA, tricyclic antidepressant. 
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3.2.2 Population based studies investigating antidepressant use and bone 
The relationship between antidepressants, especially SSRI medication and lower BMD have 
been suggested in cross-sectional and some longitudinal studies (Table 6). Some studies have 
concentrated on the use of TCAs only, with mixed results. 
 
Table 6. The studies regarding the association between antidepressant use and bone. 
 
Study Population Design Any AD SSRI TCA Other than 
SSRI or TCA
Bolton et al. 
[165] 
postmenopausal 
women 
cross-
sectional 
… negative positive no assoc. 
Diem et al.  
[166] 
postmenopausal 
women 
longitudinal 
(5 years) 
… negative no 
assoc. 
… 
Mezuk et al. 
[134] 
postmenopausal 
women 
cross-
sectional 
negative … … … 
Spangler et 
al. [116] 
postmenopausal 
women 
longitudinal 
(3 years) 
no assoc. no assoc. … … 
Eskandari et 
al. [99] 
premenopausal 
women 
cross-
sectional 
… no assoc. … … 
Petronijevic 
et al. [96] 
premenopausal 
women 
cross-
sectional 
… no assoc. no 
assoc. 
no assoc. 
Couturier et 
al. [167] 
adolescent girls cross-
sectional 
… negative … … 
Diem et al. 
[168] 
women,          
wider age range  
longitudinal 
(6 years) 
… no assoc. no 
assoc. 
… 
Williams et 
al.  [169] 
women,       
wider age range  
cross-
sectional 
… negative / no 
assoc. in some 
bone sites 
… ... 
Cauley et al. 
[170] 
older men cross-
sectional 
… negative no 
assoc. 
… 
Haney et al. 
[171] 
older men cross-
sectional 
… negative no 
assoc. 
… 
Mezuk et al. 
[134] 
older men cross-
sectional 
no assoc. … … … 
Calarge et 
al. [172] 
adolescent boys cross-
sectional 
… negative … … 
Richards et 
al. [173] 
both genders, 
older people 
cross-
sectional 
… negative … … 
Seifert et al. 
[174] 
both genders, 
young adults 
cross-
sectional 
… negative … … 
Kirjo et al. 
[175] 
both genders, 
wider age range 
cross-
sectional 
no assoc. … … … 
Abbreviations: AD, antidepressant; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant. 
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3.3 FALLS AND FRACTURES 
3.3.1 Population based studies investigating depression, antidepressants, falls and fractures 
In addition to the negative association between depression and antidepressant medication, and 
BMD and increased risk of osteoporosis, a number of studies have also shown that depression 
and use of antidepressants may increase the risk of falls and fractures. 
 
Meta-analyses have shown that use of antidepressant medication increase the risk (odds ratio, 
OR) of falling in elderly people by 36-83% [176-178], fractures by 69-94% and the relative risk 
(RR) of fractures by 39-72% [179-184]. A significantly increased risk has been found both by use 
of SSRIs and TCAs, being greater for the former. A similar association has been found in meta-
analysis investigating the effect of depression on falling (OR=1.44-1.59) [185, 186] and fractures 
(hazard ratio, HR=1.17 and risk ratio=1.52) [187] in older people. 
  
Regarding mental health, there is a preliminary analysis suggesting that life dissatisfaction 
predicts falls and hip fractures but not fractures in general [188]. Similarly, a recent study 
among Australian women showed independent associations between depression and 
antidepressant use, and falls [189]. 
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4 Study aims and hypotheses 
The aim of this study was to investigate whether life satisfaction, depression and use of 
antidepressants are associated with bone metabolism.  In addition, the study aimed to explore 
the validity of self-reported psychoactive medication use. 
 
More specifically, the aims of this study were to investigate: 
 
1. Life satisfaction as a preventive factor for BMD and bone loss in postmenopausal women 
2. Use of specific antidepressants as a risk factor for bone loss in postmenopausal women 
3. Depression and use of antidepressants as risk factors for low BMD in men 
4. Use of antidepressants as a risk factor for reduced bone quality in men 
5. Validity of self-reported psychoactive medication use including antidepressants and 
using prescription registers as a standard database 
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5 Subjects and methods 
5.1 STUDY DESIGN 
This study was based on two large population based cohorts, the Kuopio Osteoporosis Risk 
Factor and Prevention (OSTPRE) Study from Finland and Geelong Osteoporosis Study (GOS) 
from Australia.  
5.1.1 OSTPRE study (studies I-II and V) 
The OSTPRE study started in 1989. Its target population was all the 14 220 women born in 1932-
41 and residing in Kuopio Province, Finland. Out of these women, baseline postal enquiry in 
1989 was sent to 14 121 women with known and permitted address, of which 13 100 (93%) 
responded. Follow-up data has been collected via postal enquiry each 5-years (Table 7).  
 
Out of the 13 100 respondents, a stratified random sample of 3 222 women was selected for 
bone measurements in 1989-1991. The sample consisted of 2 025 randomly selected women and 
1 197 women who had undergone recent menopause or were included in certain risk group (i.e. 
women with certain diseases or medications affecting bone). Measurements were also repeated 
every 5 years (Table 7). Informed consent of the study subjects was obtained by postal enquiry. 
The study was approved by the ethics committee of Kuopio University Hospital. 
 
Table 7. OSTPRE study timetables and participants. 
 
Year(s) Study Sent Responded 
/Participants 
1989 
1989-1991 
Baseline postal enquiry 
Baseline BMD measurements 
14 121 13 100 (93%) 
3 222 
1994 
1994-1998 
5-year follow-up enquiry 
5-year BMD measurements 
13 864 12 184 (88%) 
2954 
1999 
1999-2002 
10-year follow-up enquiry 
10-year BMD measurements 
12 562 11 538 (92%) 
2833 
2004 
2004-2007 
15-year follow-up enquiry 
15-year BMD measurements 
12 936 10 926 (84%) 
2497 
2009 
2009-2011 
20-year follow-up enquiry 
20-year BMD measurements 
11 420 8 940 (78%) 
1559 
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5.1.2 GOS study (studies III and IV) 
The GOS has been carried out in south-eastern Australia and it started originally in 1993-1997 
with female population [190]. During 2001-2006, 3 273 adult men from the electoral rolls of the 
Barwon Statistical Division (study region) were randomly selected, of which 2 296 were reached 
and were capable to participate. A total of 1 540 men responded. Extensive medical, lifestyle, 
anthropometric (including BMD), nutritional, demographic and family history data was 
collected from each participant at baseline and at the 5 year follow-up (Table 8). All participants 
provided written, informed consent. The Human Research Ethics Committee at Barwon Health 
approved the study.  
 
Table 8. GOS study timetables and participants. 
 
Years Study Sent Responded  
2001-2006 Baseline enquiry together with DXA and QUS 
measurements 
2 296  1 540 (67%) 
2006-2011 5-year follow-up enquiry together with DXA and 
QUS measurements 
1 203 978 (81%) 
5.2 PARTICIPANTS 
Participants in the studies I-V were derived from the OSTPRE and GOS cohorts (Table 9). 
 
Table 9. Data settings and participants included to the studies I-V. 
 
Study Data Settings Participants 
Study I OSTPRE cross-sectional 
 
 
10-year 
longitudinal 
N = 2 167 postmenopausal women, 
who responded to the questions on life satisfaction (LS) in 
1999 and underwent 10-year bone measurements 
 
N = 1 147 postmenopausal women, 
who responded to the LS questions in 1999 and 2009 and 
underwent 10- and 20-years bone measurements 
Study II OSTPRE 5-year 
longitudinal 
N = 1 988 postmenopausal women, 
who responded to the enquiry both in 1999 and 2004 and 
underwent 10- and 15-years bone measurements 
Study III GOS  cross-sectional N = 928 men (aged 24-98 years) 
from 5-year follow-up whose BMD measurements were 
available 
Study IV GOS  cross-sectional N = 849 men (aged 24-98 years) 
from 5-year follow-up whose QUS data was available 
Study V OSTPRE cross-sectional N=11 031 postmenopausal women, 
who responded to the question determining current 
medication usage in 1999 
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5.3 DATA COLLECTION 
5.3.1 Postal enquiries 
The postal enquiries in OSTPRE study (studies I, II and V) included questions on demographic 
factors, lifestyle, nutrition, gynecological factors, consumed medication (prescribed and over-
the-counter) and dietary supplements and information about health and diseases (Table 10).  
 
Table 10. Variables from OSTPRE enquiries used in the final analyses in the studies I, II and V. 
 
Variable Explanation 
Residency  rural/city (study V) 
Marital status single/’cohabitation or married’/divorced/widowed (study V) 
Parity continuous (study I) 
Education from a densitometry subsample, categorical (study V) 
BMI calculated from weight (kg)/height(m)2: <25/25-29/30 kg/m2 (study V); for 
studies I and II, see 5.4.2 
Alcohol consumption calculated from drinks per month: none/<360/360 g pure alcohol per month 
(studies I, II and V) 
Smoking current, no/yes (studies I, II and V) 
Dietary calcium intake  calculated from daily milk (120mg/dl) and cheese (87mg/slice) products: 
continuous, mg/day (studies I and II) 
Physical activity hours per week (study V); sweaty physical activity: none/1-2/3 times per week 
(study II) 
Life satisfaction the 4-item scale, categorical: satisfied/intermediate/dissatisfied (study V); 
continuous, categorical (study I – see 5.3.2)  
Age of menarche years (study I) 
Age of menopause years (studies I and II) 
Hysterectomy no/yes (study I) 
Oophorectomy no/yes (study I) 
No. chronic health 
disorders 
continuous (study I); categorical: 0/1-2/3 (study V) 
     Depression no/yes, used as a component of a larger depression variable, see 5.5.2 (study II) 
No. prescribed 
medications 
continuous (study I); categorical: 0/1-2/3 (study V) 
     Antidepressants during 1 year before the enquiry: no/yes (study I - cross-sectional); 
during the follow-up: never/<1 year/1 year (study I - longitudinal); 
during 1 year before, 4-months before and 4-months after the enquiry (study V) 
     Bisphosphonates no/yes (studies I and II) 
     Calcium suppl. prescribed or over the counter: no/yes (studies I and II) 
     Contraceptive pills history of use: no/yes (study I) 
     Corticosteroids never/3 years/>3 years (study I); no/yes (study II) 
     Diuretics during 4-months before the enquiry (study V) 
     Hormone therapy no/yes (study I: cross-sectional, study V); 
during the follow-up: continuous, years (study I: longitudinal); 
during the follow-up: categorical, no/yes (study II) 
     Vitamin D no/yes (studies I and II) 
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The on-site filled enquiry in GOS study (studies III and IV) included demographic, lifestyle, 
health and medication questions (Table 11).  
 
Table 11. Variables from the GOS enquiry used in the analyses in the studies III and IV. 
 
Variable Explanation 
Alcohol consumption calculated from a validated food frequency questionnaire [191]: g/day 
Smoking current: no/yes 
Dietary calcium intake  calculated from a validated food frequency questionnaire [191]: mg/day 
Physical activity from a question on mobility with a 7 response option: sedentary/active 
Medication (current)  
     Antidepressants no/yes 
     Bisphosphonates no/yes 
     Calcium supplements no/yes 
     Gonadal hormones no/yes 
     Oral glucocorticoids no/yes 
     Vitamin D supplements no/yes 
 
More detailed explanation about use of these variables in each study can be found from original 
publications. 
5.3.2 Life satisfaction (studies I and V) 
Life satisfaction was included in the OSTPRE questionnaires since 1999 using the 4-item LS 
scale [192]. The items included current 1) interest in life, 2) happiness in life, 3) ease of living 
and 4) feelings of loneliness with the following responses: very interesting/very happy/very 
easy/not at all lonely = 1; fairly interesting/fairly happy/fairly easy = 2; cannot say = 3; fairly 
boring/fairly unhappy/fairly hard/fairly lonely = 4; very boring/very unhappy/very hard/very 
lonely = 5. If some of the four items was omitted, the sum score was recorded as ‘missing‘. The 
range for LS scale is 4-20, with the higher score indicating lower life satisfaction. The scale is 
also used as a 3-category variable: ‘satisfied‘ (LS score = 4-6), ‘intermediate‘ (LS score = 7-11) or 
‘dissatisfied‘ (LS score = 12-20) groups. The intermediate group consisted of those with LS score 
in one standard deviations of the mean [67]. 
 
In the study I LS was investigated both in a cross-sectional and a longitudinal setting (from 
1999 and 2009) as well as its change during this 10-year period. In the study V LS was used as a 
3-category adjusting variable and included those who answered two or more items.   
5.3.3 Major depressive disorder (studies III and IV) 
In the GOS, a lifetime history of major depressive disorder (MDD) was assessed using the 
Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Non-patient edition (SCID-I/NP) [193]. Trained personnel carried out all psychiatric 
interviews. 
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The association of lifetime MDD was investigated in the study III, where participants were 
divided into three groups: no history of MDD, a single episode, or recurrent (2) episodes of 
MDD. In study IV lifetime MDD (no/yes) was used only as an adjusting variable. 
5.4 CLINICAL MEASUREMENTS 
5.4.1 Bone measurements 
In the OSTPRE study (studies I and II), areal BMD (g/cm2) was measured at the femoral neck 
site using Dual-energy X-ray absorptiometry (DXA; Lunar DPX-IQ in 1999-2002 and Lunar 
Prodigy Pro in 2004-2007 and 2009-2011). The Lunar DPX-IQ and Prodigy results were cross-
calibrated and corrected BMD values are used accordingly [194]. 
 
In the GOS, areal BMD (g/cm2) was measured at the forearm, spine, total hip and total body 
using DXA (Lunar Prodigy Pro in 2006-2011) (study III). Quantitative Ultrasound (QUS) was 
used as a measurement of heel bone quality (Lunar Achilles InSight Ultrasonometer in 2006-
2011) (study IV).  It was used to determine the Broadband Ultrasound Attenuation (BUA; 
dB/MHz), Speed of Sound (SOS; m/sec) and Stiffness Index (SI; %) (see 2.1.1). 
 
Trained technicians carried out all examinations and performed calibrations of the 
densitometers and ultrasonometer. 
5.4.2 Other measurements 
In the OSTPRE study, at the time of DXA, also height and weight as well as grip strength were 
measured. Changes in weight were calculated based on 1999 and 2004 (study II) or 1999 and 
2009 (study I) measurements. Body mass index (BMI) was calculated as weight (kg)/height (m) 
squared from 1999 measurements. Grip strength was measured in a valid environment using 
pneumatic squeeze dynamometer, Martin Vigorimeter (kPa) in 1999-2002. The mean of the 
three successive measurements on the dominant hand was used in the study I. Grip strength 
has been found to be a good general measure of muscle strength [195] and a measure of physical 
activity in healthy female subjects [196]. 
 
In the GOS, at the time of bone measurement, height and weight were measured to the nearest 
0.1 cm and 0.1 kg, respectively (studies III and IV). 
5.5 REGISTRATION DATA 
5.5.1 The National prescription register (studies I, II and V) 
The OSTPRE data was linked with the National prescription register (from the Social Insurance 
Institution of Finland; Kela) by personal identification codes. This prescription register contains 
data from all the reimbursed prescription medicines which have been purchased in any 
pharmacy in Finland [197]. It does not include information on 1) medication use in hospitals or 
community nursing homes, where medicines are included in the services; 2) medications which 
are not reimbursable such as small packages costing under a fixed deductible share (i.e. 8.41 € in 
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1999) unless being a specially refunded medicine due to the selected chronic diseases including 
psychosis; 3) medications which have been purchased without reimbursement [197]. 
 
Medications were selected according to the Anatomical-Therapeutic-Chemical- (ATC) codes 
[82]. For longitudinal analyses, the use of medication was measured as Defined Daily Doses 
(DDD), which explains the assumed average maintenance dose per day for a medication used 
for its main indication in adults [82]. It allows the comparison between different medicine 
agents under the main medication group. In general, 360 DDD corresponds to approximately 
one year of use. 
 
In the study I antidepressants was used only as an adjusting variable. Participants were 
regarded as users of antidepressants (ATC-codes N06A, N06CA) in 1999 and 2009 cross-
sectional analyses if they, according to the prescription register, had purchased any 
antidepressant during the preceding 12 months before their assessment of LS. For longitudinal 
analysis, the use of antidepressants during the follow-up was measured as DDDs and 
categorized (none/<360/360 DDDs). 
 
The study II the use of antidepressants (N06A, N06CA) was investigated also as subgroups. 
Groups of only tricyclic antidepressants (TCA; N06AA, N06CA01), only selective serotonin 
reuptake inhibitors (SSRI; N06AB), only other (N06AX) and a group of several different 
antidepressants (poly) use were studied more specifically. Participants were originally regarded 
as a user of antidepressants if they had purchased any antidepressant between the BMD 
measurements in 1999 and 2004. In further analyses the purchasing of antidepressants as DDDs 
was used in two different ways: A) as a dichotomous (no/yes) and B) as a continuous variable. 
For a first part (A), participants were coded as users (actual users), if they had purchased 
antidepressants more than 30 DDDs (i.e. more than “trial period”) in 1999-2004. For the second 
part (B), any use of DDDs was divided by 100. If participants used more than one different 
antidepressant, but used another antidepressant 30 DDDs or less, they were coded according to 
the most used antidepressant, not as a poly antidepressants user. 
 
Purchasing of any psychoactive medication (ATC: N05, N06) and more specifically 
antidepressants (N06A, N06CA) and other psychoactive medications (N05, N06B, N06CB, 
N06D) was used as subgroups of the study V. In addition, anti-dementia medication (N06D) 
and psychostimulants/nootropics (N06B) was used as an adjusting memory variable and 
diuretics (C03) as a reference for psychoactive medications. Psychoactive medication purchased 
from a pharmacy within four months before the response to enquiry in 1999 as DDD tertiles 
was used in this study. For checking purposes were used also 12 months before and a 4-month 
after response periods. 
5.5.2 Other registers (studies I, II and V) 
The OSTPRE data was linked also with other nationwide registries by personal identification 
codes. The Finnish Hospital Discharge Register (from the National Research and Development 
Centre for Welfare and Health; STAKES/THL) provided information on hospitalizations due to 
depression and the National Register for Work Disability Pensions (from Kela) was used to 
obtain information on disability pensions. 
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In study I, hospitalizations were used as follows: hospitalizations in 1989-1999 (no/yes) for 
cross-sectional study in 1999 and hospitalizations in 1999-2009 (no/yes) for longitudinal study 
and cross-sectional study in 2009. 
 
In study II, depression was treated as a 3-category variable (no / only self-reported depression / 
work disability or hospitalization due to depression). Participants were coded suffering from 
depression if they self-reported it either in 1999 or 2004 (category 1) or were hospitalized or had 
granted a disability pension due to depression between 1999 and 2004 (category 2). 
 
In study V, history of work disability due to somatic or psychiatric cause until 1996 was used. 
5.5.3 Socio-economic status (studies III and IV) 
Socio-economic status (SES) (studies III and IV) was ascertained using Socio-Economic Index 
For Areas (SEIFA) index scores, based on the 2006 Australian Bureau of Statistics Census data. 
It was then used to derive an Index of Relative Socio-economic Advantage and Disadvantage 
(IRSAD) score accounting for high and low income, and type of occupation [198]. A low score 
identifies the most disadvantaged (quintile 1), while a high score identifies the most advantaged 
(quintile 5).  
5.6 STATISTICAL ANALYSES 
Statistical analyses performed using the SPSS statistical package 17.0 and 19.0 for Windows 
(SPSS Inc., Chicago, IL, USA). 
 
Endpoint variables: 
1. Femoral neck BMD (BMDfem; mg/cm2) in 1999 and 2009 and annual percent change of 
BMDfem between 1999 and 2009 (study I) 
2. Annual percent change of BMDfem between 1999 and 2004 (study II) 
3. Forearm, spine, total hip and total body BMD (in 2006-2011) (study III) 
4. Calcaneus heel QUS values SI (%), BUA (dB/MHz) and SOS (m/sec) (in 2006-2011) (study 
IV) 
5. Purchased psychoactive medication/antidepressants/other psychoactive medication in 
1999 (study V) 
 
Putative causal variables: 
1. Self-reported life satisfaction in 1999 and 2009 and its change between 1999 and 2009 
(study I) 
2. Purchased antidepressant medication (TCA, SSRI, others, poly use) between 1999 and 
2004 (study II) 
3. A lifetime history of MDD and self-reported antidepressant use (in 2006-2011) (study III) 
4. Self-reported antidepressant use  (in 2006-2011) (study IV) 
5. Self-reported use of psychoactive medication/antidepressants/other psychoactive 
medication in 1999 (study V) 
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Bone loss of femoral neck between two measurements was calculated as follows: (BMDfem2-
BMDfem1)/time between measurements/BMDfem1*100% (studies I and II). 
 
The sensitivity (% true positives) and specificity (% true negatives) for self-reported 
psychoactive medication was used with the National prescription register data as a reference in 
the study V. Sensitivity was calculated as follows: a/(a+b) and specificity: d/(c+d), where a= self-
reported and purchased, b= not self-reported but purchased, c= self-reported but not purchased, 
d= not self-reported, not purchased. 
 
The main analytic methods are ANOVA, GLM, linear and logistic regression and paired t-test. 
Differences between LS groups were examined with the Chi-squared test for category variables 
and ANOVA for continuous variables. In case of non-normal distribution for category variables, 
Kruskal-Wallis test was used. 
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6 Results 
6.1 CHARACTERISTICS OF THE STUDY POPULATIONS 
The mean age of the OSTPRE women was 62 years and GOS men 60 years (Table 12).  
 
Table 12. Characteristics of the OSTPRE women and GOS men study populations in 1999 and 2006-
2011, respectively. Values are given as mean (SD), median (IQR) or numbers (%). 
 
Variables All OSTPRE (n=11 538) 
BMDfem measured in 
OSTPRE (n=2 219) 
All GOS (n=978) 
Age (yr) 62.2 (59.8-64.7) 61.9 (59.8-64.2)* 60.0 (46.1-73.2) 
BMI (kg/m2)a 26.9 (24.3-30.1) 26.7 (24.2-30.0)* 27.2 (24.7-29.6) 
Dietary calcium (mg/day)b 857.8 (385.1) 862.5 (364.6) 930.8 (364.8) 
BMD (g/cm2)   
      Femoral neck - 0.880 (0.125) - 
      Total neck - 1.002 (0.145) 1.066 (0.148) 
      Lumbar spine (L2-4) - 1.107 (0.168) 1.293 (0.198) 
      Total body - - 1.241 (0.110) 
      Forearm - - 0.419 (0.064) 
Alcohol users  5 701 (51.4%) 1 187 (54.5%)* 834 (89.3%) 
      Alcohol intake (g/day) 3.4 (4.1) 3.4 (4.1) 21.4 (20.8) 
Smokers 944 (6.5%) 180 (8.1%)* 110 (11.3%) 
Users of medicationc    
      Bisphosphonates 341 (2.4%) 142 (6.4%)* 17 (1.7%) 
      Calcium  supplements 982 (6.8%) 238 (10.7%) 57 (5.8%) 
      AD 492 (4.3%) 82 (3.7%) 67 (6.9%) 
      AD (during 1 year)d 1 131 (7.8%) 196 (8.8%)* - 
      Hormone therapy 2 745 (19.0%) 732 (33.0%)* 3 (0.3%) 
      Corticosteroids  1 268 (13.8%) 323 (15.4%)* 10 (1.0%) 
Life satisfaction  *  
      Satisfied 2 685 (18.6%) 539 (24.3%) - 
      Intermediate 6 960 (48.1%) 1 394 (62.8%) - 
      Dissatisfied 1 439 (10.0%) 234 (10.5%) - 
Work disability or hospitalization due 
to depressione 510 (4.4%) 104 (4.7%) 
- 
Mood disordersf 255 (1.8%) 36 (1.6%) - 
Current mood disordersg - - 21 (2.1%) 
MDD in lifetimeg - - 144 (14.7%) 
Abbreviations: AD, antidepressants; BMD, bone mineral density; BMI, body mass index; IQR, interquartile range; 
MDD, major depressive disorder; SD, standard deviation. a OSTPRE: self-reported weight and height, GOS: 
measured; b OSTPRE: daily milk and cheese, GOS: from food frequency questionnaire (FFQ); c Current, self-
reported; d From pharmacy registries; e History of work disability (temporary disability or permanent pension) up 
to 1999 or hospitalization between 1980 and 1999, register-based; f Also previously detected, self-reported 1999; g 
From clinical interview (SCID-I/NP). * P <.05 compared to non-measured. 
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6.2 LIFE SATISFACTION AND BONE LOSS IN POSTMENOPAUSAL WOMEN 
(STUDY I) 
6.2.1 Cross-sectional associations 
The satisfied had the highest and the dissatisfied had the lowest BMDfem in cross-sectional 
analyses in 1999 and 2009 (Table 13). In 1999 cross-sectional analysis the satisfied had 1.8% 
greater BMDfem in unadjusted and 1.5% greater BMDfem in adjusted models when compared 
them to the dissatisfied (Table 13), but the differences were significant only when compared 
satisfied to all others (P=.010 and P=.040, respectively). In 2009 the differences were more 
remarkable (Table 13). 
 
Table 13. Unadjusted and adjusted mean BMDfem (mg/cm2) in 1999 and 2009 by categorical LS. 
 
LS in 1999 (n=2 167) BMD (95% CI) in 1999 % * P value * 
Unadjusted    
    Satisfied (n=539; 24.9%) 892.3 (882.2, 902.4) +1.8 .10 
    Intermediate (n=1 394; 64.3%) 876.4 (869.1, 883.0) +0.0 .99 
    Dissatisfied (n=234; 10.8%) 876.4 (860.4, 892.4) - - 
Adjusted    
    Satisfied 893.5 (882.6, 904.3) +1.5 .11 
    Intermediate 880.8 (873.9, 887.6) +0.5 .66 
    Dissatisfied 876.6 (859.7, 893.6) - - 
LS in 2009 (n=1 380) BMD (95% CI) in 2009 % * P value * 
Unadjusted        
    Satisfied (n=298; 21.6%) 860.5 (847.1, 874.0) +5.1 <.001 
    Intermediate (n=919; 66.6%) 846.6 (838.6, 854.6) +3.4 .007 
    Dissatisfied (n=163; 11.8%) 818.6 (801.1, 836.1) - - 
Adjusted    
    Satisfied 852.8 (839.5, 866.1) +3.4 .045 
    Intermediate 847.8 (840.2, 855.4) +2.3 .067 
    Dissatisfied 829.1 (810.6, 847.5) - - 
Abbreviations: BMDfem, femoral neck bone mineral density; CI, confidence interval; LS, life satisfaction. Adjusted for 
age, BMI, smoking, grip strength, hospitalization due to depression (during 10 years before enquiry), use of 
bisphosphonates, hormone therapy, corticosteroids, antidepressants (during one year before the enquiry) and 
dietary calcium. Performed with ANOVA and analysis of covariance via GLM procedure. * Compared to the 
dissatisfied. 
 
When studying the association between LS and BMD in 1999 by using linear regression, LS as a 
3-category was associated with BMDfem (adjusted model: B=-9.48, P=.033) such as above 
mentioned, but as a continuous variable, there was no significant association. The inclusion of 
grip strength and use of corticosteroids to the models weakened the associations in cross-
sectional models. Other adjustments such as use of alcohol, vitamin D, number of diseases or 
medications, history of disability pension or hospitalizations due to depression, history of use of 
oral contraceptive pills, age of menarche and menopause, parity, oophorectomy and 
hysterectomy did not affect the relationship between LS and BMD. 
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6.2.2 Longitudinal associations 
Women who were satisfied in 1999 or whose life satisfaction had improved between 1999 and 
2009 had the least and women who were dissatisfied or whose life satisfaction had deteriorated 
had the most bone loss during 10-year period (Table 14).  
 
After adjustments women who belonged to the dissatisfied group in 1999 had 58% (P=.024) 
more bone loss annually during 10-year period compared to the satisfied. Similarly, women 
whose life satisfaction deteriorated (i.e. LS score increased more than 2 units) during 10-year 
period had 89% (P=.006) more bone loss annually than women whose life satisfaction improved 
(i.e. LS score decreased more than 2 units) (Table 14). 
 
Table 14. Adjusted mean annual percent BMDfem change in 1999-2009 by categorical LS and LSc 
change. 
 
 
Annual % BMDfem change  
Mean (95% CI) P value * 
LS in 1999 (n=1 147)   
     Satisfied (n=300; 26.2%) -0.36 (-0.44, -0.28) .024 
     Intermediate (n=744; 64.9%) -0.44 (-0.48, -0.39) .10 
     Dissatisfied (n=103; 9.0%) -0.57 (-0.71, -0.42) - 
LSc change a in 1999-2009   
    < - 2 units (n=145; 12.6%) -0.28 (-0.42, -0.14) .006 
    No/minor change ( ± 2 units) (n=814; 71.0%) -0.43 (-0.48, -0.38) .052 
    > + 2 units (n=188; 16.4%) -0.53 (-0.64, -0.43) - 
Hospitalization in 1999-2009   
    No -0.42 (-0.46, -0.38) .014 
    Yes -0.95 (-1.36, -0.53) - 
Abbreviations: BMDfem, femoral neck bone mineral density; CI, confidence interval; LS, life satisfaction; LSc, 
continuous LS. Adjusted for LS change/LS, age, BMI, smoking, grip strength, dietary calcium and current use of 
bisphosphonates and corticosteroids in 1999 as well as weight change, hospitalization due to depression and use of 
hormone therapy and antidepressants between 1999 and 2009. Performed with analysis of covariance via GLM 
procedure. a Positive LSc change value indicates improving in LS score -> decreasing in life satisfaction. * Compared 
to dissatisfied, deteriorated or hospitalized -group. 
 
When studied the association more precisely using linear regression, both LS as a 3-category 
and a continuous variable were associated with bone loss in multivariate models such as above 
mentioned (Table 15). 
 
Table 15. Longitudinal analyses with annual change in BMDfem (%) as the outcome. 
 
 Unadjusted models Adjusted models 
Variables  B  t P value B  t P value 
(Constant) - - - 0.035 0.07 .95 
LS (3-category) a -0.051 -1.49 .14 -0.089 -2.25 .024 
Change of LS b 0.008 1.105 .27 0.027 3.23 .001 
Hospitalization due to depression c -0.492 -2.40 .016 -0.538 -2.54 .011 
(Constant) - - - 0.049 0.09 .93 
LS (continuous) d -0.007 -0.88 .38 -0.022 -2.20 .028 
Change of LS b 0.008 1.105 .27 0.031 3.30 .001 
Hospitalization due to depression c -0.492 -2.40 .016 -0.523 -2.47 .014 
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Abbreviations: B, unstandardized beta coefficients; BMDfem, femoral neck bone mineral density; LS, life satisfaction 
Adjusted for age, BMI, smoking, grip strength, dietary calcium and current use of bisphosphonates and 
corticosteroids in 1999 as well as weight change and use of hormone therapy and antidepressants between 1999 
and 2009. a In 1999: satisfied, intermediate, dissatisfied; b Change of continuous LS in 1999-2009: higher score 
indicates improvement in life satisfaction; c No/yes in 1999-2009; d In 1999; range 4 to 20, higher score indicates 
lower life satisfaction. 
 
The association of hospitalization due to depression and bone loss in 1999-2009 was also 
significant (Tables 14 and 15), even though the number of hospitalized patients was low (n=11). 
Women with hospitalization due to depression had over double more bone loss compared with 
women without hospitalization during the study period (Table 14). No association between 
hospitalization and BMD was seen in cross-sectional analyses. 
 
Other variables such as number of diseases, prescribed medication, use of vitamin D or alcohol 
use did not attenuate the associations.  
6.3 ANTIDEPRESSANT USE AND BONE LOSS IN POSTMENOPAUSAL WOMEN 
(STUDY II) 
According to the prescription register, a total of 319 (16.0%) of the 1 988 participants had 
purchased antidepressants during the 5-year follow-up. Of the participants, 92 (4.6%) had used 
only TCAs, 118 (5.9%) only SSRIs and 56 (2.8%) only other antidepressants, while 52 (2.6%) 
women were poly users. Moreover, one woman had used MAO inhibitors. Mean baseline 
BMDfem was 881.1 mg/cm2 (SD 123.1) and the 5-year bone loss was -6.0 mg/cm2 (SD 4.7). 
 
In the univariate model, TCA use was significantly associated with bone loss compared to the 
non-users during the 5-year period (-16.1 vs. 5.4 mg/cm2, P=.028). In addition, use of any 
antidepressants was associated with bone loss after excluding the use of other antidepressants 
(Table 16). After adjustments, only TCA use as a dichotomous variable was associated with 
greater bone loss also in the fully adjusted model (Table 16).  
 
Table 16. Adjusted mean annual BMDfem changes (mg/cm2 or %) according to the antidepressant 
subgroups compared to the non-users. 
 
 mg/cm2 (95% CI) %  (95% CI) 
No use a -1.06 (-1.52, -0.60) -0.08 (-0.13, -0.03) 
Any -2.07  (-3.33, -0.80) -0.17* (-0.31, -0.03) 
Any without other ADs -2.76** (-4.13, -1.39) -0.24* (-0.39, -0.08) 
TCA only -3.60** (-5.85, -1.35) -0.35** (-0.61, -0.10) 
SSRI only -2.81* (-4.80, -0.81) -0.22 (-0.44, 0.01) 
Other ADs only 1.73* (-1.39, 4.84) 0.22 (-0.14, 0.57) 
Poly use -1.00  (-3.97, 1.97) -0.07 (-0.41, 0.26) 
Abbreviations: AD, antidepressant; BMDfem, femoral neck bone mineral density; CI, confidence interval; SSRI, 
selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant. Adjusted for age, BMI, baseline BMD, weight 
change, smoking, use of alcohol, bisphosphonates, corticosteroids, hormone therapy, calcium and vitamin D 
supplements, dietary calcium, physical activity, grip strength, age of menopause and depression. Performed by 
analysis of covariance with GLM procedure. a No use of antidepressants or use <30 DDDs in 1999-2004. * P <.10, ** 
P <.05 compared to the non-users. 
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When the association was studied using continuous variable (i.e. amount of purchased 
medication) only the use of SSRIs was linearly and significantly related to increased bone loss 
(linear regression, adjusted model: B=-0.046 per 100 DDDs, P=.001). In addition, use of other 
antidepressants was associated with bone loss, but only among low and normal weight women 
with weight loss (P=.016). More detailed information of the relationship between antidepressant 
use and bone loss can be found from the original publication II. 
6.4 MAJOR DEPRESSIVE DISORDER (MDD), USE OF ANTIDEPRESSANTS 
AND BMD IN MEN (STUDY III) 
6.4.1 Cross-sectional associations between MDD and BMD  
Recurrent MDD was significantly related to lower forearm and total body BMD (P=.023 and 
P=.038, respectively) corresponding to -5.0% and -2.4% lower BMD than in men with no MDD 
history, respectively in adjusted models (Table 17). On the other hand, a single MDD episode 
was associated with higher total hip BMD (P=.038, corresponding to +3.1%). 
 
Table 17. Unadjusted and adjusted BMDs at forearm, spine, total hip and total body BMD (g/cm2) as 
outcome by MDD status. 
 
 No MDD 
n=794 (85.6%) 
Single MDD 
n=84 (9.1%) 
Recurrent MDD 
n=50 (5.4%) 
Bone site g/cm2 (95% CI) g/cm2 (95% CI) % * P value g/cm2 (95% CI) % * P value 
Unadjusted        
   Forearm  0.418 (0.41, 0.42) 0.435 (0.42, 0.45) 4.1 .017 0.409 (0.39, 0.43) -2.2 .36 
   Spine  1.298 (1.28, 1.31) 1.281 (1.24, 1.33) -1.3 .48 1.244 (1.19, 1.30) -4.2 .067 
   Total hip 1.062 (1.05, 1.07) 1.108 (1.08, 1.14) 4.3 .008 1.058 (1.02, 1.10) -0.4 .85 
   Total body 1.239 (1.23, 1.25) 1.266 (1.24, 1.29) 2.2 .038 1.230 (1.20, 1.26) -0.7 .59 
Adjusted        
   Forearm  0.418 (0.41, 0.42) 0.429 (0.42, 0.44) 2.6 .13 0.397 (0.38, 0.41) -5.0 .023 
   Spine  1.297 (1.28, 1.31) 1.301 (1.26, 1.34) 0.3 .84 1.254 (1.20, 1.31) -3.3 .16 
   Total hip 1.063 (1.05, 1.07) 1.096 (1.07, 1.13) 3.1 .038 1.033 (0.99, 1.07) -2.8 .15 
   Total body 1.240 (1.23, 1.25) 1.256 (1.24, 1.28) 1.3 .14 1.210 (1.18, 1.24) -2.4 .038 
Abbreviations: BMD, bone mineral density; CI, confidence interval; MDD, major depressive disorder. Adjusted for 
age, weight, height, calcium intake, current use of antidepressants, bisphosphonates and calcium or vitamin D 
supplements. Performed with analysis of covariance via GLM procedure. * Compared to men with no MDD. 
 
Associations between BMD and MDD were similar before and after including antidepressant 
use and other relevant covariates into the models. 
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6.4.2 Associations between use of antidepressants and BMD  
In univariate analysis antidepressant users had lower total hip BMD (P=.039) than non-users 
(Table 18) corresponding to -3.7% lower BMD than non-users. 
 
Table 18. Unadjusted forearm, spine, total body and total hip BMDs (g/cm2) according to use of 
antidepressants. 
 
 Non-users 
n=863 (93.0%) 
Antidepressant users 
n=65 (7.0%) 
Bone site g/cm2 (95% CI) g/cm2 (95% CI) % * P value 
Forearm  0.419 (0.42, 0.42) 0.410 (0.39, 0.43) -2.1 .27 
Spine  1.296 (1.28, 1.31) 1.260 (1.21, 1.31) -2.8 .16 
Total hip 1.068 (1.06, 1.08) 1.029 (0.99, 1.07) -3.7 .039 
Total body 1.242 (1.24, 1.25) 1.223 (1.20, 1.25) -1.5 .18 
Abbreviations: BMD, bone mineral density; CI, confidence interval. * Compared to the non-users. 
 
Weight was an effect modifier in the relationship between antidepressant use and BMD. In 
adjusted models, BMD was lower for the antidepressant users compared to the non-users in 
men with low weight in all bone sites (forearm P=.003, lumbar spine P=.027, total hip P<.001 and 
total body P=.001). The weight cut-off points varied between BMD sites from 75kg to 110kg 
being highest when the total hip BMD was studied. Adjustments included lifetime MDD which 
did not changed the results. More detailed information about the weight interaction can be 
found from the original publication III. 
6.5 USE OF ANTIDEPRESSANTS AND BONE QUALITY IN MEN (STUDY IV) 
In univariate analysis antidepressant users had lower mean BUA and a similar, but non-
significant trend was seen with SI (Table 19). 
 
Table 19. Unadjusted quantitative ultrasound (QU) SI (%), BUA (dB/MHz) and SOS (m/sec) values 
according to use of antidepressants (AD). 
 
 Non-users 
788 (92.8%) 
AD users 
61 (7.2%) 
  
QU site value (SD) value (SD) % * P value 
BUA (dB/MHz) 120.8 (15.9) 115.7 (16.2) -4.2 .020 
SOS (m/sec) 1572.5 (40.9) 1566.9 (47.4) -0.4 .32 
SI (%) 100.2 (20.2) 95.4 (23.0) -4.8 .076 
Abbreviations: BUA, broadband ultrasound attenuation; SD, standard deviation; SI, stiffness index; SOS, speed of 
sound. * Compared to non-users. 
 
In the adjusted models antidepressant use was associated with lower BUA, SOS and SI (P=.053, 
P=.010 and P=.002), but the association interacted with weight: values were lower for 
antidepressant users with lower body weight only. The weight cut-off points varied between 
QUS parameters from 85kg to 105kg being the highest when BUA was studied. Adjustments 
included lifetime MDD which did not changed the results. More detailed information about the 
weight interaction can be found from the original publication IV. 
 
35 
 
 
6.6 VALIDATION STUDY ON SELF-REPORTED PSYCHOACTIVE MEDICATION 
USE (STUDY V) 
Self-reported use of medication was compared to the prescription register data within a 4-
month time window preceding the response to enquiry. Only 44% out of 1 638 women who 
were purchased psychoactive medication reported their use (Table 20).  The rate was higher for 
the use of antidepressants (55%) than for the use of other psychoactive medications (29%). After 
excluding the occasional use (i.e. expanding prescription register data to 12-month), an increase 
in sensitivity by approximately 10 percentage points was seen regardless of the group of 
psychoactive medication. Self-reported use of diuretics covered a much higher percentage (83%) 
of the register-based data than the use of psychoactive medication when studying a 4-month 
period (Table 20). Users of psychoactive medication also reported their use of diuretics less 
accurately (76%) than non-users (85%) (P=.001). 
 
Table 20. Comparison of self-reported psychoactive medication and diuretics use to the National 
prescription register. 
 
 Self-reported           
 
Any psychoactive  
medication 
 
Antidepressants 
 
 
Other 
psychoactive 
medication 
without 
antidepressants 
Diuretics b 
 
  
Prescription 
register yes no yes no yes no yes no 
Yes a 724 914 426 351 250 611 1 039 210 
No 152 9 241 66 10 188 344 9 826 197 9 585 
Sensitivity 0.44  0.55  0.29  0.83  
Specificity 0.98  0.99  0.97  0.98  
appa 0.527* 0.652* 0.299* 0.815* 
a Purchased the given medication within four months before response to postal enquiry; b The group includes all 
diuretics users. * P <.001 
 
High use of studied psychoactive medication (e.g. antidepressants) and history of work 
disability pension due to psychiatric cause were associated with a much higher likelihood of 
reporting studied psychoactive medication use (Table 21). In the multivariate models, greater 
alcohol consumption was associated with lower sensitivity for reporting the use of 
antidepressants. In respect to marital status, those who were single had higher sensitivity for 
reporting their medication use than others. Higher number of any self-reported prescribed 
medication, higher use of antidepressants or any psychoactive medication according to the 
prescription register and work disability pension due to psychiatric cause were all associated 
independently with higher sensitivity, while work disability pension due to somatic cause was 
associated with lower sensitivity. In women using any psychoactive medication, improved 
sensitivity between self-report and register-based data was associated with younger age.  
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Table 21. Sensitivity (%) of self-reported antidepressant use by characteristics of the study subjects 
compared with the National prescription register data during four months preceding the self-report. 
 
Characteristics % (N reported / N all purchased) P value* 
Self-reported use of antidepressants 54.8 (426/777)   
Marital status   .021 
        single 70.0 (56/80)  
        married / cohabiting 54.8 (251/458)  
        divorced 51.7 (45/87)  
        widowed 48.9 (69/141)  
No. of self-reported prescribed medication   <.001 
        0 0.0 (0/35)  
        12 40.8 (115/282)  
         3 67.6 (311/460)  
Amount of purchased antidepressants a   <.001 
        low 35.4 (85/240)  
        moderate 56.8 (151/266)  
        high 70.1 (190/271)   
History of work disability pension   <.001 
        no 51.4 (231/449)  
        somatic cause 47.4 (99/209)  
        psychiatric cause 80.7 (96/119)   
a Tertile cutoffs for amount of use: low <33 / moderate 33-99.9 / high 100 (Defined Daily Doses /4 months). 
* P value from the chi-square test between the subgroups. 
  
37 
 
 
7 Discussion 
7.1 THE ASSOCIATION BETWEEN MENTAL HEALTH AND BONE 
MEASUREMENTS 
Bone health was investigated in respect to self-reported life satisfaction, registry-based 
hospitalizations due to depression (OSTPRE) and episodes of lifetime MDD based on structured 
diagnostic interviews (GOS). Self-reported life satisfaction and its improvement were associated 
with reduced bone loss among Finnish postmenopausal women. Also hospitalization due to 
depression, independent of life satisfaction, was associated with increased bone loss. Similarly, 
a negative association was evident for Australian men; those with a history of recurrent MDD 
had lower forearm and total body BMD. All these associations were sustained following 
multiple adjustments. 
 
A number of studies, both in women and men, have reported a negative association between 
depression and BMD or bone loss. Although, to my knowledge, there are no other studies 
investigating the association between self-reported subjective well-being and BMD. Previously, 
Erez et al. [113] studied mental stress and found its negative association with BMD in 
postmenopausal women. This was not seen in another study of women (spanning a larger age 
range), but an increased fracture risk in those having long-term distress was, however, reported 
[141]. Now, in the OSTPRE, using life satisfaction as a broad indicator of subjective well-being, 
representing both poles (negative/positive) of mental health, both continuous LS and its 
improvement were associated with reduced bone loss. Annual BMD change was 1.6 times 
higher among the dissatisfied than the satisfied (-0.57% vs. -0.36%) and increase in life 
satisfaction in the follow-up slowed bone loss (-0.28% vs. decrease -0.53%/year). Also, 
hospitalization due to depression had an independent association with annual bone loss, with 
2.3 times higher loss among those with than without it (-0.95%/year vs. -0.42%/year). 
Previously, in another 5-year study with postmenopausal women, a similar significant 
difference at the femoral neck was found: those with depressive symptoms had 1.7 higher bone 
loss than those without (-0.88%/year vs. -0.51%/year) [112]. This was seen also at the total hip 
but not at the trochanter. In contrast, two large longitudinal studies with 3-year [116] and 5-year 
follow-ups [127] among postmenopausal women and women with wider age range, 
respectively, found no association between depressive symptoms and bone loss. However, the 
first one studied only forearm BMD, but the second included hip, spine and total body. 
 
This study was able to determine single and recurrent episodes of lifetime MDD as well as 
continuous life satisfaction and severe hospitalized depression and the increasing negative 
association with bone along with the increasing dissatisfaction or depression severity was 
found. Previously, number of episodes [96, 102, 134, 136], severity [96, 98, 102, 119, 123, 129, 134, 
199] or duration of depression [98, 102, 134, 136, 199] in respect to bone has been studied only 
by some. No association between number of depressive episodes has been reported and only 
one study has been published suggesting longer episode [96] to be associated with lower BMD. 
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The methods have also varied greatly between studies. The duration range for depression in the 
Petronijevic et al. [96] study was 2-15 years. In contrast, Yazici et al. [98] studied de novo 
depression with the mean duration being six months, while others focused on longer 
depression period or a lifetime history. However, only two of these studies did not find any 
association between depression and lower BMD [102, 199]. Some other studies have found the 
severity [119, 123, 129] of depression to be increasingly associated with the lower BMD. Charles 
et al. [126] found the increased severity of depression to be associated with lower BMD in 
women but not in men. In addition, Wu et al. [138] showed in a meta-analysis that severe 
depression was associated with an additional decrease in BMD. 
 
In most of the studies among men, both clinically diagnosed depression and depressive 
symptoms have been associated with reduced BMD. Using the GOS data, significantly lower 
forearm (-5.0%) and total body BMD (-2.4%) in men with a recurrent history of MDD compared 
with those without was found. Similarly, using large age group, Williams et al. [127] found 2.6% 
lower forearm BMD in men with depressive symptoms compared those without. In addition, 
Mussolino et al. [120] found 2.8% lower and Wong et al. [132] 2.1% lower total hip BMD 
compared depressed and non-depressed young adults and older man, respectively. In contrast 
to the findings of the present study, Wong et al. [132] found no association with depression 
using total body BMD, but similar to the present study, no association with spine BMD was 
seen either. 
 
In contrast to the negative associations between recurrent MDD and forearm and total body 
BMD, single episode MDD was positively associated with total hip BMD. Still, there was a lack 
of important knowledge on timing, duration or possible past successful treatment of single 
episode. In addition, the group with no MDD episode may include participants with sub-
threshold depression or prolonged stress without diagnosis and treatment [200], which could 
affect the results. Moreover, a single-episode of depression may be qualitatively different, being 
more psychological and related to an adjustment reaction to stressors, as opposed to recurrent 
depression, which is likely to be more biological and activate neuroprogressive pathways such 
as inflammation, oxidative stress and apoptosis, which can predispose to osteoporosis [201-203]. 
 
The results show the increasing negative association on bone along with increased 
depressiveness or decreasing mental health. They also underscore the importance of assessing 
subjective well-being in the general population in addition to just a diagnosis-based approach 
when identifying the risks of osteoporosis. 
7.2 THE ASSOCIATION BETWEEN USE OF ANTIDEPRESSANTS AND BONE 
In postmenopausal women, accelerated bone loss during 5-years of follow-up was seen in users 
of TCA and SSRI. In addition, accelerated bone loss was noticed in low and normal -weight 
women who lost weight and were using other antidepressants. The deleterious association of 
antidepressants and bone was present also in Australian men, but similarly, only in those with 
lighter body weights. These associations were independently present after adjusting for a wide 
range of possible confounding variables. 
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To my knowledge, QUS, SI, BUA and SOS values measured using QUS have not been 
previously investigated in association between antidepressant use and bone. In the present 
studies, the same male population was used when investigating both QUS and DXA. Together 
they confirmed that use of antidepressants has a negative association on bone, but only in men 
with lower weight. Before adjustments antidepressant use was significantly associated with 
3.7% lower total hip BMD and 4.2% lower calcaneal BUA value compared to non-use. After 
adjustments the significant independent association was seen in all sites but only among lower 
weight men. Association between SSRI medication and low BMD has previously been seen in 
studies both in men and women and different age groups. For example, users of SSRI have 
shown 4.7% lower femoral neck and 4.6% lower lumbar spine BMD compared to non-users in 
age and weight -adjusted models among older men [170]. Similarly Haney et al. [171] found 
3.9% lower multiple adjusted femoral and 5.9% lower multiple adjusted spinal BMD in older 
men using SSRIs compared to non-users. Use of TCAs has not been previously associated with 
low BMD [170, 171]. 
 
To my knowledge, there are no previous studies to investigate, not only SSRIs or TCAs, but also 
‘other antidepressants’ and poly use as well as purchased amount of antidepressants. Diem et 
al. [166] had a similar 5-year follow-up of postmenopausal women (mean age, 78.5 years) 
showing the association between SSRI use and accelerated bone loss. They reported 0.82% 
annual mean total hip bone loss in SSRI users compared with 0.47% in non-users. In the present 
study was not found such a great bone loss with OSTPRE women (mean age, 64 years in 1999) 
at the femoral neck nor a significant difference between SSRI users and non-users (-0.22% vs. -
0.08%, respectively). No association between SSRI use and bone loss was evident in a 3-year 
follow-up study in postmenopausal women either [116]. Similarly to the present study, Seifert 
et al. [174] found decreasing bone density along with increasing of SSRI duration on young 
adults in a cross-sectional study. In addition, TCA users had significantly greater bone loss than 
non-users (-0.35% vs. -0.08%, respectively) which Diem et al. [166] did not found. Diem et al. 
[168] did not found either any bone differences between TCA users and non-users or even 
between SSRI users and non-users in a 6-year longitudinal study when including both pre- and 
postmenopausal women [124].  
 
The weight interaction was present in both OSTPRE and GOS study populations. However, in 
OSTPRE postmenopausal women it was found only in the group using the ‘other 
antidepressants’, whereas among GOS men, it applied to ‘any antidepressant use’, including all 
types of antidepressants. Thus, this pooling in GOS could have diluted the effects of certain 
subgroups. Still, because the majority of men used SSRIs (72%), the reason why weight-
interaction in the OSTPRE study was seen only in women using other antidepressants or 
otherwise, why it affected to the results when studying any antidepressant use in GOS-men, 
remains unclear. Previously, weight interaction has been seen in the study of Williams et al. 
[127] on the association between depressive symptoms and forearm BMD in women. However, 
this interaction acted in an opposite way: they found lower BMD for heavier women with 
depressive symptoms but not for lower weight women as in OSTPRE study. 
 
The reasons why negative antidepressant association was seen only among low-weight men 
and women according to use of other antidepressants can be speculated. This weight effect has 
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not been shown in previous studies or in OSTPRE women using TCAs or SSRIs. One reason 
might be that different types of depression (i.e. melancholic or atypical) could lead to different 
type of response on bone, although depression in general was statistically controlled for. Severe 
(melancholic) depression induces weight loss, stress response and hypercortisolism, whereas 
atypical depression is associated with the opposite i.e. weight gain and lower cortisol and stress 
factor levels [204]. In the effects of body weight on bone, also the amount of fat tissue as well as 
different biological effects of antidepressant subgroups may play a role. High leptin 
concentration secreted by adipocytes and fat tissue [103] has been found to be beneficial to bone 
mass [109, 205]. Leptin seems, for example, to directly increase osteoblast proliferation and 
differentiation via leptin receptors in bone [206, 207]. However, opposite skeletal effects 
depending on the origin of fat tissue have been found: subcutaneous fat, the main source of 
leptin and adiponectin, is beneficial to bone, whereas visceral fat have negative effect to bone 
due to its ability to produce more pro-inflammatory cytokines [208, 209]. In addition, serotonin 
receptors and transporters are found to be expressed in adipocytes [110, 210] and the 
antidepressant therapy may have effect also via this way. However, both increased [211, 111] 
and decreased [212] or non-changed [111] leptin levels during antidepressant therapy have been 
reported. Without taking into account the possible effects of antidepressant medication via 
adipocytes, participants with higher body weight are likely to have more fat tissue with higher 
concentrations of adipocytes and leptin, which might overshadow the negative associations 
between antidepressant use and bone. Furthermore, the positive association between BMD and 
weight might also reflect the adaptive effect of load bearing on bone turnover. However, the 
association between bone, body mass and use of antidepressants is unclear and there may be 
many confounding mechanisms behind this association. 
 
All in all, a negative association between antidepressant use and bone measurements was 
shown in both men (with lower body weight) and women. With postmenopausal women, TCA 
and SSRI use was evidenced to increase bone loss as was the use of other antidepressants 
among low-weight women only. Thus, the use of antidepressants should be noted as a risk 
factor for lowered bone density in these groups. 
7.3 VALIDITY OF SELF-REPORTED PSYCHOACTIVE MEDICATION USE 
Register-based data seems to ensure more realistic information on the use of psychoactive 
medication than self-report when also irregular use and medication for milder psychiatric 
disorders need to be taken into account.  
 
Results showed that 44% of the postmenopausal women report their use of any psychoactive 
medication and 55% report their use of antidepressants as response to a question on current use 
of prescribed medicines in a postal enquiry when register-based data on purchased medication 
was used as a reference. When the reporting of diuretics (80%) was assessed, the sensitivity was 
much lower. However, the sensitivity of self-report of antidepressants increased considerably 
with higher use, with a history of work disability pension due to psychiatric cause or when 
occasional use was excluded. In addition, women who did not respond to the enquiry had used 
psychoactive medication more often than the responders. 
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Other Finnish studies have previously found a higher overall agreement for antidepressants 
(sensitivity, 0.68-0.92) and antipsychotics (0.77-0.91) using the same prescription register as in 
the present OSTPRE study [213-215]. However, some differences can be found in these studies, 
compared to the present study. Haukka et al. [215] and Haapea et al. [213] used 6-month 
purchasing time window preceding the enquiry. However, Rikala et al. [214] used the same 4-
month time window, as in the present study, and found still very high agreement for both 
antidepressants (0.92) and antipsychotics (0.91). In fact the sensitivities were lower only after 
when they expanded the time window to 12-months (0.82 and 0.86, respectively). This might be 
explained by the fact that participants remember better the medication used recently than 
longer time ago. Still, only Haapea et al. [213] had similar postal enquiry than in the present 
study; Rikala et al. [214] and Haukka et al. [215] used interview and in Haukka et al. [215] 
study, participant were also requested to bring their prescriptions with them to interview, 
which may have led to better results. Moreover, Haukka et al. [215] and Haapea et al. [213] used 
younger population and Rikala et al. [214] older than in the present study. 
 
When studies with foreign database are considered, a large study by Nielsen et al. [216] with 
home interview but pharmacy records as a reference, found sensitivity of self-reported 
antidepressant use (56%) and psycholeptics & antidepressants (44%) similar to ours. Nielsen et 
al. [216] used 3-month time window and the data was derived from same period as in the 
present study. Also Boudreau et al. [217] found similar sensitivity for antidepressants (66%) 
when using interview with specific medication questions and 6-month time-window. Nielsen et 
al. [216] found low sensitivity also for psycholeptics (38%) and especially for hypnotics and 
sedatives (27%). Thus, the low sensitivity in the present study (29%) for the group of other 
psychoactive medication might be due to the high proportion of users of hypnotics and 
sedatives in this group. The use of hypnotics and sedatives is usually occasional, which may 
explain the low sensitivity. In addition, the risks of long-term use of benzodiazepines and 
sedatives have previously been discussed, when the present study was carried out [218, 219]. 
The long-term use of sedatives is not recommended, thus, participants may have preferred not 
to disclose due to feeling stigmatized. These issues are not similarly associated with use of 
antidepressants. 
 
In the present OSTPRE study, users of psychoactive medication showed lower sensitivity also 
for reporting the use of diuretics than non-users of psychoactive medication, but, still, they 
reported the use of diuretics better than the use of psychoactive medication. Also in previous 
studies, the use of psychoactive medication has been less accurately reported than other 
medications [216, 217]. Psychoactive medicines such as hypnotics may not be used as regularly 
as diuretics. Thus a participant may feel that occasional use is not important enough to be 
mentioned in a questionnaire. On the other hand, it should be taken into account that medicine 
may not be used at the moment or at all after purchase. Lin et al. [220] found that 28% of 
patients discontinued their antidepressant medication during the first month of therapy and 
44% by the third month of therapy. Still, in case of the use of antidepressants and psychoactive 
medication, self-perceived shame or unwillingness may hinder the reporting the use [200]. It 
seems that regular use of antidepressants and long-term severe mental illness are the most 
important correlates of sufficient self-report. 
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7.4 STRENGTHS AND LIMITATIONS 
 
The strengths of these studies include large population-based samples, the OSTPRE female 
sample from Finland and the GOS male sample from Australia. Bone health was studied against 
several indicators of mental health i.e. self-reported life satisfaction, hospitalization due to 
depression and lifetime MDD episodes as well as against use of antidepressant medication. 
Measuring bone health by using both DXA with several measurement sites and calcaneal QUS 
on the same GOS population strengthened the liability of the found results. A wide age range 
was allowed in the GOS studies, whereas the narrow age range increased the homogeneity of 
the OSTPRE studies. High response rates allowed also estimation of the representative 
population effects. These data sets included extensive questionnaire and additional registry 
based data. Thus, it was possible to adjust for several potential confounding factors. When 
investigating antidepressant use, adjustment for depression improved the reliability of the 
results. The same was applied, when life satisfaction or depression was the exposure and 
medications the covariates.  
 
Epidemiologic studies have always a risk of confounding. Information bias is possible in studies 
based on enquiries. Inaccurate recall or response may have affected the found associations. 
However, it is not likely that these inaccuracies differed by outcome or biased the relationships 
found in these studies. The present studies included both cross-sectional and longitudinal 
studies which give valuable but different perspectives to the study questions, although, cross-
sectional studies do not allow investigation of causal relationships. Using self-reported 
antidepressant data and the cross-sectional study designs did not allow for the effects of 
duration of use or dosage to be explored. Also the investigation of antidepressant subgroups 
was restricted due to study power constraints. In the OSTPRE study, antidepressant use was 
derived from the prescription register which provides a higher accuracy even if use is 
occasional. A limitation in the prescription register is that it does not verify the actual use or the 
exact daily dosage. Participants might have also discontinued the medication. In addition, 
prescription register provides information only for reimbursement packages which have been 
purchased from a pharmacy. 
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8 Conclusions 
Studies of this thesis showed that poor mental health, either diagnosed depression or decreased 
life satisfaction, has negative associations on bone in both postmenopausal women and in men. 
These studies also showed negative associations between TCA and SSRI use and bone in 
postmenopausal women. In addition, use of ‘other antidepressants’ was associated with bone 
loss in low-weight women, as was the use of any antidepressants in lower weight men. 
 
Self-reported medication use via postal enquiry seems to be a sufficient indicator of regular use 
of antidepressant medication and any psychoactive medication use for subjects with severe 
psychiatric disease. However, prescription register data gives a more accurate indication of 
those who are using these medications irregularly or suffer from less severe mental disorders. 
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9 Recommendations 
Severe depression as well as milder psychological symptoms i.e. life dissatisfaction seems to be 
associated with poor bone metabolism. Prevention of depression, its early detection and 
appropriate medical care may thus be important issues in the prevention and care of 
osteoporosis or lowered bone density in both men and women. Furthermore, focusing on 
improving subjective well-being might be one of the approaches that should be considered to 
decrease adverse effects of aging on bone. 
  
The risk of effects on bone should be taken into account when prescribing antidepressants for 
men and women. For postmenopausal women with already heightened risk of osteoporosis, 
long-term treatment of depression with high doses of TCAs and SSRIs should be monitored and 
interrupted if use is not required. 
 
Further research with sufficient sample size focusing on subgroups of antidepressants and body 
weight on bone health is needed. Differentiation of subtypes of depression 
(melancholic/atypical) in these studies might also provide additional information. 
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APPENDIX I 
The 10-year postal enquiry 
 
 
 
  
 
 
 
Osteoporosis Prevention Study – 10-year follow-up enquiry 
Kuopio University Hospital and University of Kuopio 
10.05.1999 
 
 
To whom it may concern 
 
Kuopio University Hospital and the University of Kuopio started Osteoporosis Risk Factor and 
Prevention Study (OSTPRE) in 1989. A postal enquiry was sent to all the 14 000 women born in 
1932-41 and living in the Province of Kuopio. You belonged to this group. The 5-year follow-up 
enquiry was carried out in 1994. Over 90% of you answered both enquiries. We thank you for your 
positive attitude. Furthermore, a randomly selected sample of 3 000 women will undergo bone 
mineral density measurements every 5 years. 
The aim of the OSTPRE Study is to study osteoporosis but also women’s health and factors affecting 
health. This is possible if we have enquiry and measurement information on the healthy and the sick 
for over a long-term time period. 
It is now the time for the 10-year follow-up enquiry. We kindly ask you to fill this enquiry form by 
answering every question so that you circle the right answer alternative matching your situation and 
write the asked information in the space reserved for the answer. If you don’t remember the asked 
matter, an estimate is enough. It is important that everyone responds even if you no longer live in 
North Savo area/Kuopio Province. If you need help in filling the enquiry, you can call the telephone 
number (017) 162 978. The information you give is confidential and will be published only as 
statistical tables so that your identity remains secret. 
We thank you in advance for the effort to respond the enquiry. 
PS. Herewith we send OSTPRE study results so far in a nutshell. 
 
Seppo Saarikoski Esko Alhava Risto Honkanen 
MD, Professor MD, Professor MD, PhD, Docent  
Department of Gynecology Department of Surgery University of Kuopio 
 
 Heikki Kröger Marjo Tuppurainen 
 MD, PhD, Docent MD, PhD, Consultant 
 Department of Surgery Department of Gynecology 
 
 
 
QUERY SECTION STARTS 
FAMILY INFORMATION 
 
1. Has your mother had a wrist or hip fracture? 
  1 No 
  2 Yes, a wrist fracture 
  3 Yes, a hip fracture 
  4 Yes, both wrist and hip fracture 
 
2. Has your mother had a breast cancer? 
  1 No 
  2 Yes, at the age of _____ 
 
3. Is your mother still alive? 
  1 Yes 
  2 No, she died at the age of_____ 
 
4. Has your father had a wrist or hip fracture? 
  1 No 
  2 Yes, a wrist fracture 
  3 Yes, a hip fracture 
  4 Yes, both wrist and hip fracture 
 
5. Is your father still alive? 
  1 Yes 
  2 No, he died at the age of_____ 
 
6. How many brothers and sisters do you have? 
 ____ sisters and ____ brothers 
 
7. Have your sisters had a wrist or hip fracture? 
  1 No 
  2 Yes, a wrist fracture at the age of __ 
  3 Yes, a hip fracture 
  4 Yes, both wrist and hip fracture 
 
8. Have your sisters had a diagnosed breast cancer?  
  1 No 
  2 Yes, at the age of ____ 
 
9. Have your brothers had a wrist or hip fracture? 
  1 No 
  2 Yes, a wrist fracture at the age of __ 
  3 Yes, a hip fracture 
  4 Yes, both wrist and hip fracture 
 
 
PERSONAL INFORMATION 
Fractures 
 
10.   Have you had fractures diagnosed by a physician 
since 1st of May 1994? 
  0 No, move to the question 11 
  1 Yes, bone sites and dates? 
   ________________________     ___/___19____ 
   ________________________     ___/___19____ 
   ________________________     ___/___19____ 
 
  How did you get above-mentioned fractures? 
  1 Fall, slipping ………............  19____  19____  
  2 Fall, otherwise …………….  19____  19____ 
  3 Fall from height, ___meters ………    19____ 
  4 Bicycle crash………………………    19____ 
  5 Car crash…………………………...    19____ 
  6  Otherwise, how? 
   _______________________________ 19____ 
  
  Where were the above-mentioned fractures 
diagnosed and treated? 
  _______________________________  19____ 
       _______________________________  19____ 
  _______________________________ 19____ 
 
 
Fall overs and fall offs 
 
11. Have you fallen on level or from height during the 
preceding 12 months? 
  0 No, move to the question 16 
  1 Yes, how many times? 
  ______ times 
 
12. In which month did you fall last time? 
 1 January 5 May   9 September 
 2 February 6 June 10 October 
 3 March 7 July 11 November 
 4 April 8 August  12 December 
 
13. Where did you fall last time? 
  1 Outdoors 
  2 Indoors 
 
14. How did you fall last time? 
  1  Fall on stairs 
  2  Fall from height? ____meters 
  3  Fall on level due to slipping 
  4  Fall on level due to stumbling 
  5  Fall on level, otherwise, how? 
____________________________________ 
 
15. Did you consult a physician due to your last time 
fall? 
  1 No 
  2 Yes, no fracture was diagnosed 
  3 Yes, a fracture was diagnosed 
 
 
Menstruation 
 
16. How old were you when you had your first 
periods? 
  ______- years old 
 
17. How old were you, when you had your last natural 
(non hormonal) periods? 
  ______ - years old 
 
 Please tick here, if hormone therapy was started 
before your last natural periods. 
 
 Please tick here, if your uterus was removed 
before your last natural periods.  
 
 
 
 
 
 
 
Life situation 
 
18. Do you think that your life is very interesting, 
quite interesting, quite sad or very sad at the 
moment?  
  1 Very interesting 
  2 Quite interesting 
  3 Quite sad 
  4 Very sad 
  5 I can’t say 
 
19. Do you think that your life is very happy, quite 
happy, quite unhappy or very unhappy at the 
moment? 
  1 Very happy 
  2 Quite happy 
  3 Quite unhappy 
  4 Very unhappy 
  5 I can’t say  
 
20. Do you feel that your life is very easy, quite easy, 
quite hard or very hard at the moment? 
  1 Very easy 
  2 Quite easy 
  3 Quite hard 
  4 Very hard 
  5 I can’t say 
 
21. Do you think that you are very lonely, quite lonely 
or not at all lonely at the moment? 
  1 Very lonely 
  2 Quite lonely 
  3 Not at all lonely 
  4 I can’t say 
 
22.  What is your current marital status? 
  1 Unmarried 
  2 Cohabiting 
  3 Married 
  4 Divorced 
  5 Widowed 
 
 
Work, work ability and pension 
 
23. What is your work situation at the moment? 
  1 I am working 
  2 I am unemployed  
  3 I am retired  
  4  I am unable to work in long term - but not yet 
retired 
  5 I am working and part time pensioner 
 
24. What is your current occupation or what was 
your last profession?  
 _____________________________________ 
 _____________________________________ 
 
25. How many years you have been at this work? 
 _________years 
 
 
 
26. How hard is/was this work physically? 
  1 Sedentary (e.g. secretary, teacher) 
  2 Light (e.g. nurse, salesman)  
  3 Medium heavy (e.g. cleaner, nurse aid) 
  4 Heavy (e.g. farmer, stock worker) 
 
Next question only for the retired. 
 
27. What was the reason for your retirement? 
  1 Age 
  2 Work disability 
  3 Age and disability (individual early  
   retirement)  
  4 Unemployment 
 
Next question only for the retired due to disability 
 
28. Which illness caused your disability pension?  
 _______________________________________ 
 _______________________________________ 
 _______________________________________ 
 
 
Body measurements 
 
29. What was your height at the age of 25? 
  ________cm 
 
30. What is your height at the moment? 
  ________cm 
 
31. What was your weight at the age of 25? 
  ________kg 
 
32. What is your weight at the moment? 
  ________kg 
 
33.  What is your waist circumference? (Measure in 
standing position without clothing in the end of 
expiration without tightening measuring tape. 
Measurement line below)      
 
 
  _____cm 
 
 
 
 
 
 
 
 
Health habits 
 
34.  Are you smoking currently? 
  0 No 
  1 Yes, approx.  ____ cigarettes per day 
 
35.  How many deciliters of dairy products (milk, sour 
milk, yogurt, sour whole milk) do you use daily at 
present?  
 On average ________ dl 
 
36.  How many slices of cheese do you take daily at  
 present? 
 On average _______ slices 
 
37. What is the amount of alcohol beverages you are 
consuming monthly? (write down 0 if you do not use 
at all) 
   
 Beer on average    ____ bottles 
 Wine on average   ____ glasses 
 Spirits on average ____ grogs 
 
38. What is your mobility? 
  1 Fully capable to move 
  2 Capable to move, but unable to run 
  3 I can walk 1 km at the most 
  4 I can walk 100 m at the most 
  5 I can move only indoors 
  6 I am not able to move at all 
 
39. How many kilometers have you been walking or 
running a week overall during the preceding year 
(12 months), including trips to and from work and 
moving at work? 
 
  On average 
  ______ km weekly in winter  
  ______ km weekly in summer 
 
40.  Have you had regular leisure physical activity 
during the preceding year?      (e.g. walking, Nordic 
walking, bicycling, skiing, swimming, dancing, 
running) 
 
  1  No 
  2 Yes, how many hours a week? 
  
 On average   ____hours a week in winter  
 On average   ____hours a week in summer 
 
41. Which sports have been your main leisure sports 
during the preceding year? 
 
In winter __________________________________ 
 __________________________________________ 
 In summer _________________________________ 
 __________________________________________ 
 
 
 
 
42. How physically strenuous has your leisure sports 
been? (strenuous = causing perspiration or 
shortness of breath) 
 
 In winter 
1 Light (e.g. walking, physical jerks)  
2 Medium (e.g. fast walking, dancing) 
  3    Heavy (e.g. swimming, ball games) 
  4    Very heavy (e.g. running, skiing) 
 
 In summer 
  1    Light (e.g. walking, physical jerks) 
  2  Medium heavy (e.g. fast walking, bicycling) 
  3    Heavy (e.g. swimming, ball games) 
  4    Very heavy (e.g. running) 
 
 
Health 
 
43. What is the best alternative to describe your 
current health status compared to others of your 
age? 
  1 Very good 
  2  Good 
  3 Moderate 
  4 Not good 
  5 Poor 
 
44. What was the best alternative to describe your health 
status 5 years ago compared to others of your age? 
  1 Very good 
  2  Good 
  3 Moderate 
  4 Not good 
  5 Poor 
 
45. Has a physician diagnosed following diseases in 
You? (Circle all alternatives you have and record the 
year of diagnosis) 
   Year of diagnosis 
 
 1  Sight impairment affecting moving ................ ____  
   2  Hypertension requiring drug treatment............ ____ 
 3  Coronary heart disease (infarct, angina).......... ____ 
   4  Other heart disease (e.g. heart failure) ............ ____ 
 5  Apoplexy…………………………................. ____ 
 6 Cerebral thrombosis ……………………….... ____ 
 7 Cerebral hemorrhage ……………………….. ____ 
 8 Cerebral embolus……………………………. ____ 
 9 High blood cholesterol………………………. ____ 
 10 Venous thrombosis in lower limb…………… ____ 
 11  Diabetes treated with insulin........................... ____  
 12  Diabetes requiring tablet treatment.................. ____ 
 13  Hyperthyroidism............................................. ____  
 14  Hypothyroidism.............................................. ____ 
 15 Lactose intolerance………………………….. ____ 
 16 Celiac..……………………………………… ____ 
 17 Stomach resection........................................... ____ 
 18 Chronic kidney disease................................... ____ 
 19 Chronic liver disease....................................... ____ 
 20 Rheumatoid arthritis………………………… ____ 
 21 Arthrosis affecting moving............................. ____ 
 22 Sciatic back pain radiculating leg…………... ____ 
 
 
 
  23 Sciatic pain due to disc herniation…………... ____ 
 24 Sciatic pain caused by spinal stenosis………. ____ 
 25 Other chronic back pain…………………….. ____ 
 26 Epilepsy…………………………… ……….. ____ 
 27 Pulmonary asthma…………………………... ____ 
 28 Other chronic pulmonary disease.................... ____ 
 29 Alcoholism………………………………….. ____ 
 30 Chronic mental disease.................................... ____ 
 31 Breast cancer………………………………… ____ 
 32 Uterine cancer……………………………….. ____ 
 33 Cervical cancer……………………………… ____ 
 34 Other cancer, specify ……………………………... 
 ______________________________________  ____ 
  
 35 Other chronic/severe diseases, specify?
 ______________________________________  ____ 
 ______________________________________  ____ 
 
 0 None of the above-mentioned or other chronic or 
severe diseases 
 
46. If you have/had joint degeneration due to 
osteoarthritis, specify the joints and years of 
diagnosis? 
  1 Hip …………………………. 19____ 
  2 Knee ………………………...   19____ 
  3  Spine  ……………………….   19____ 
  4  Cervical spine ………………   19____ 
  5  Fingers ………………………  19____ 
  6  Other joints, which? 
  ___________________________  19____ 
 
47. How long has your longest sick leave due to back 
pain been? 
  1 No sick leave due to back pain 
  2 One week or less 
  3 8-29 days 
  4 1-3 months 
  5 Over 3 months 
 
48. Have you had acute back pain of over one month 
during the preceding 12 months? 
 0 No 
 1  Yes, in upper back 
 2  Yes, in lower back 
 
 
Medications 
 
49. Do you use at present drugs prescribed by a 
physician? If you use, record names of the 
products and duration of treatment in years. 
 0 I don’t use 
 1 I use 
 
  Names of drugs, duration of use, years 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
 
 
50. Have you ever used cortisone as tablets (e.g. 
Prednisolon, Medrol) for at least one week? 
  1 No 
  2 Yes, first time in year 19 _____ 
 
51. Have you ever used cortisone as bronchial or 
nasal inhalation for at least one week? 
  1 No 
  2 Yes, first time in year 19 _____ 
 
52. What is your total lifetime use of cortisone in 
years or months? Estimate by adding all 
treatments of at least one week duration. 
  ____years______months as tablets 
  ____years______months as inhalations 
 
53. Have you used estrogen hormone as tablets, 
plaster or gel after 1st May 1994 e.g. for 
menopausal symptoms or osteoporosis 
prevention? (Vaginal tablets, salve or sticks 
excluded)  
 
  1 No 
  2 Yes; specify months of use and name of 
product for each year 
 
    Product name 
  1994  ___months_________________________ 
  1995  ___months_________________________ 
  1996  ___months_________________________ 
  1997  ___months_________________________ 
  1998  ___months_________________________ 
  1999  ___months_________________________ 
 
54. Do you use estrogen hormone as tablets, plaster or 
gel at the moment? 
 1 No 
 2 Yes 
 
55. Do you use calcium as a pharmaceutical or 
natural product? 
  1 No 
  2 Yes, as pharmaceutical product 
  3  Yes, as natural product 
  4 Yes, as both products 
 
Names of the products  
  _______________________________________
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
 
56. Do you use vitamin D at the moment? 
  1 No 
  2 Yes 
 
  Names of the products 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
 
 
 
 
57. Do you use any other osteoporosis medication? 
(e.g. Fosamax, Didronate, Miacalcic, Bonefos, 
Evista, Livial, Skelid, Bondronate) 
 
  1 No 
  2 Yes, name of the product 
________________________________________
________________________________________ 
 
  Duration of treatment  ____years____months 
 
 
Surgical operations 
 
58.  Has your uterus been removed since 1st May 
1994? 
  1 No 
  2 Yes, in year 19____ 
 
59. Have your both ovaries been removed? 
  1 No 
 2 Yes, year when the last/second ovary was 
removed 19_____ 
 
60. Have you ever been in spinal surgery operation?  
  1 No 
  2 Yes, in years 19____, 19____, 19____ 
 
61. Have you ever been in a joint prosthesis or joint 
position correction operation? 
  1  No 
  2  Yes, hip …………………... year 19____ 
  3 Yes, knee ………………… year 19____ 
  4 Yes, other joint ……………year 19____ 
   which joint? _______________________ 
 
62. Have you been in any other surgical operation 
since 1st May 1994?  
  1 No 
  2 Yes, in years 19____, 19____ 
 
 What was operated? 
________________________________________ 
 ________________________________________ 
 ________________________________________ 
 
 
Other hospitalizations 
 
63. Have you been hospitalized for any other reason 
than surgical operation since 1st May 1994? 
  1 No 
  2 Yes, in years 19__, 19 __, 19__ 
   
 Illnesses?__________________________________ 
 __________________________________________ 
 
 
 
 
 
 
 
Your contact information? 
 
Phone number 
 Home or mobile phone  _____-___________________ 
 Work ………………… _____-___________________ 
 Other ………………… _____-___________________ 
 
Address (if changed) 
_______________________________________________ 
_______________________________________________ 
_______________________________________________ 
 
 
 [ identification sticker ] 
 
 
Consent 
 
Finally, we request you to give us your written consent 
with signature for use of your medical records. We may 
need medical record information in studies on factors that 
affect bone loss and health. 
 
I give the Kuopio Osteoporosis Study permission to use 
my medical records.  
 
Signature 
______________________________________________ 
 
Date  ______.______1999 
 
 
THANK YOU FOR YOUR ANSWERING 
Please check that you answered to every question, fold the 
form and mail it in enclosed return envelope as soon as 
possible. No stamp is needed.  
 
Other information  
_______________________________________________ 
_______________________________________________ 
_______________________________________________ 
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Associations between Life 
Satisfaction, Depression, 
Antidepressant Use, and Bone 
Osteoporosis and resultant fractures 
are an increasing health problem 
worldwide. The early detection of 
possible risk factors can help the pre-
vention of osteoporosis. This study 
investigated whether life satisfaction, 
depression and use of antidepres-
sants are associated with bone health 
using two large population based 
cohorts. 
